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Dear Prof. Steinbuchel, 
 
Revised Manuscript Submission to Applied Microbiology and Biotechnology 
 
Thank you for sending us the comments and suggestions from the review process on our mini-
review "Recent advancements in high-level synthesis of the promising clinical drug, 
prodigiosin". 
 
We thank the reviewers for the suggestions to improve the content of this review on 
prodigiosin production from its natural host and from heterologous hosts. We have made all 
the suggested changes which have been itemized in the Response to Reviewers’ Comments 
document and the major changes have been highlighted in the revised manuscript. 
 
We feel that the current version of the mini-review is greatly improved from the original 
version and will be of importance to those interested in prodigiosin as well as microbiologists 
working on large-scale production of multi-gene-encoded recombinant proteins. All authors 
approve the manuscript in its current form for resubmission to Applied Microbiology and 
Biotechnology.  We hope that the Editorial Board will consider this revised manuscript 
suitable for publication in Applied Microbiology and Biotechnology. 
 
Thank you 
 
Sheila Nathan 
School of Biosciences & Biotechnology,  
Faculty of Science and Technology,  
Universiti Kebangsaan Malaysia,  
43600 Bangi, Selangor DE, Malaysia  
Email: sheila@ukm.edu.my 
Cover Letter
Response to Reviewers’ Comment 
Manuscript ID AMAB-D-18-02760 
Title Recent advancements in high-level synthesis of the promising 
clinical drug, prodigiosin 
Authors Chee-Hoo Yip, Orr Yarkoni, James Ajioka, Kiew-Lian Wan 
and Sheila Nathan 
 
We would like to thank the reviewers for the comments and suggestions to improve 
this mini-review. We have addressed all the points raised by the individual reviewers 
below: 
 
Reviewer A 
The mini-review paper entitled "Recent advancements in high-level synthesis of the 
promising clinical drug, prodigiosin" presents an overview on prodigiosin research in 
last decades. The mini-review is comprehensive and well written, however it is not 
sufficiently novel to set it apart from few recent reviews within the field and there is 
not sufficient material to warrant publication in AMB in its current form. 
The intention of Yip and co-authors was to give overview on the prodigiosin 
production in its natural host Serratia marcescens, through recombinant and synthetic 
biology approaches for safe and cost-effective production of prodigiosin. However, 
the most of the review has been dedicated to description of the biosynthetic genes that 
has been done on numerous occasions in similar reviews. Thus, out of 97 references 
in total, 58 are older than 2014.  
 
We thank the reviewer for the comments. We have re-aligned the focus of the mini-
review to the recombinant and synthetic approaches previously undertaken to produce 
prodigiosin and concurrently edited the description that relates to the biosynthesis of 
prodigiosin in its original host, Serratia marcescens. In doing this, we have also 
updated the literature and the related references. 
 
In addition, I was not able to recognise references for the original work done by 
the authors within the subject. 
 
The Malaysian authors in collaboration with the co-authors in the United Kingdom 
are currently working on synthesising prodigiosin in Escherichia coli using a 
synthetic biology approach. In parallel with the work on cloning the 12 pig genes into 
E. coli, we are also developing new tools for gene cassette integration as well as 
codon optimization for expression in E. coli. These 2 aspects of the project have 
recently been published: 
  
(1) Yip CH, Yarkoni O, Ajioka J, Wan KL, Nathan S (2018) Development of a codon 
optimization strategy using the eforRED reporter gene as a test case. AIP Conf Proc 
1940. pp. 020080. doi: 10.1063/1.5027995;  
(2) Yip CH, Yarkoni O, Mario J, Ajioka J, Wan KL, Nathan S. The Escherichia coli 
motA flagellar gene as a potential integration site for large synthetic DNA. Sains 
Malaysiana. In press  
 
Authors' Response to Reviewers' Comments Click here to access/download;Authors' Response to
Reviewers' Comments;Yip et al AMAB-D-02760 Response to
In addition the co-authors in the United Kingdom have published on the use of 
synthetic biology: 
 
(1) Haseloff J & Ajioka J (2009) Synthetic biology: history, challenges and prospects. 
J R Soc Interface 6:S389-S391. doi: 10.1098/rsif.2009.0176.focus  
(2) Juhas M & Ajioka JW (2015b) Identification and validation of novel chromosomal 
integration and expression loci in Escherichia coli flagellar region 1. PLoS One 10. 
doi:10.1371/journal.pone.0123007  
(3) Juhas M & Ajioka JW (2016a) High molecular weight DNA assembly in vivo for 
synthetic biology applications. Crit Rev Biotechnol 37. doi: 
10.3109/07388551.2016.1141394  
(4) Juhas M & Ajioka JW (2016b) Integrative bacterial artificial chromosomes for 
DNA integration into the Bacillus subtilis chromosome. J Microbiol Methods 125:1-7. 
doi: 10.1016/j.mimet.2016.03.017  
(5) Juhas M, Evans LDB, Frost J, Davenport PW, Yarkoni O, Gillian MF, Ajioka JW 
(2014) Escherichia coli flagellar genes as target sites for integration and expression 
of genetic circuits. PLoS One 9. doi:10.1371/journal.pone.0111451. 
 
My recommendation is to reduce the part on the biosynthesis of prodigiosin and 
remove or condense corresponding figures.  
 
We agree with the reviewer that the sections related to prodigiosin biosynthesis should 
be reduced. As noted above, we have condensed the text related to the biosynthetic 
pathway of prodigiosin (page 4, lines 33-37). Also, we have combined Figures 3, 4 
and 5 into one single figure (new Figure 3) (page 5, line 14) that summarises the 
bifurcated pathway to produce prodigiosin. 
 
Instead, more information is needed on the downstream processing to obtain pure 
prodigiosin including overview of the extraction and separation techniques from 
the original and recombinant hosts. 
 
We agree with the reviewer that the downstream processes to obtain pure prodigiosin 
have not been extensively reviewed in the previous literature related to prodigiosin 
production. To enhance the content of this mini-review, we have included the section 
titled ‘Isolation and Purification of Prodigiosin from S. marcescens’ (page 11, lines 
24-36 and page 12, lines 1-34). 
 
Figure 1 should contain characterised prodigiosin derivatives in addition to 
prodigiosin. 
 
We have improved Figure 1 by incorporating several prodigiosin derivatives: 
undecylprodigiosin, cycloprodigiosin, metacycloprodigiosin, prodigiosin R1 and 
streptorubin B) (page 2, line 10). 
Reviewer B 
Overall the review is nice, and very thorough. I would recommend that figure 3, 4 
and 5 is joined into one figure. That would make it easier to follow. 
We thank the reviewer for his/her suggestion. We have combined the original Figures 
3, 4 and 5 into one single figure (new Figure 3) (Page 5, line 14). 
Else, there are only minor spelling mistakes, which should be corrected. 
We thank the reviewer for highlighting the spelling errors. We have proofread the 
manuscript and edited the spelling errors. 
The revised manuscript with major changes highlighted is appended below. 
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Abstract 
Prodigiosin, a red linear tripyrrole pigment and a member of the prodiginine family, is normally 
secreted by the human pathogen Serratia marcescens as a secondary metabolite. Studies on prodigiosin 
have received renewed attention as a result of reported immunosuppressive, antimicrobial and 
anticancer properties. High-level synthesis of prodigiosin and the bioengineering of strains to 
synthesise useful prodiginine derivatives have also been a subject of investigation. To exploit the 
potential use of prodigiosin as a clinical drug targeting bacteria or as a dye for textiles, high-level 
synthesis of prodigiosin is a prerequisite. This review presents an overview on the biosynthesis of 
prodigiosin from its natural host Serratia marcescens and through recombinant approaches as well as 
highlighting the beneficial properties of prodigiosin. We also discuss the prospect of adopting a 
synthetic biology approach for safe and cost-effective production of prodigiosin in a more industrially 
compliant surrogate host. 
 
Introduction 
Prodigiosin is a red bacterial pigment that is secreted as a secondary metabolite. It is the most 
prominent member of the prodiginine family (other members include undecylprodigiosin, 
cycloprodigiosin, metacycloprodigiosin, prodigiosin R1 and streptorubin B) (Fig. 1) (Stankovic et al. 
2014). Prodigiosin has long been a subject of research interest due to its many potential beneficial 
properties that include anticancer (Elahian et al. 2013), antimicrobial (Ibrahim et al. 2014) and 
antimalarial (Papireddy et al. 2011) properties. This metabolite is secreted by a number of 
microorganisms such as Hahella chejuensis (Kim et al. 2006), Streptomyces coelicolor (Do and 
Nguyen 2014), Streptomyces grisiovirides (Kawasaki et al. 2008), Serratia nematodiphila (Darshan 
and Manonmani 2016), Serratia rubidae (Siva et al. 2011) and Serratia marcescens (Casullo de Araujo 
et al. 2010). Driven by the potential development and application of prodigiosin as a clinical drug, 
many studies have been undertaken to dissect its biosynthetic pathways as a means to increase 
production of this pigment. Nevertheless, attempts to develop prodigiosin as a therapeutic molecule 
have been hampered by reports of toxicity on eukaryotic cells (Pandey et al. 2009), its ability to 
intercalate and cause double stranded DNA breaks (Kimyon et al. 2016) as well as cell cycle arrest 
(Soto-Cerrato et al. 2007). Furthermore, purified prodigiosin is reportedly immunosuppressive on the 
human immune response (Liu and Nizet 2009). Taken together, prodigiosin was presumed to be 
cytotoxic towards eukaryotic cells and therefore, not suitable to be developed as a clinical drug. 
 
Fig.1 Members of the prodiginine family. A) prodigiosin B) undecylprodigiosin C) 
cycloprodigiosin D) metacycloprodigiosin E) prodigiosin R1 and F) streptorubin B 
(Adapted from PubChem (Kim et al. 2016)). 
 
 Nevertheless, recent studies have shown that prodigiosin is not genotoxic (Guryanov et al. 
2013). Furthermore, bacterial prodigiosins and their synthetic derivatives are effective pro-apoptotic 
agents against various cancer cell lines where multiple cellular targets include multi-drug resistant cells 
with little or no toxicity towards normal cell lines (Elahian et al. 2013; Kavitha et al. 2010). These 
findings pave the way for prodigiosin to be developed as a promising drug candidate and efficient 
production of this microbial pigment is the prerequisite to its full clinical evaluation. However, large 
bacterial cultivation of S. marcescens for high prodigiosin production is not safe and there are limited 
reports on the expression of prodigiosin in a safer heterologous host for high-level synthesis.  
 
Hence, this review focuses on the organisation of the prodigiosin biosynthesising or pigment (pig) 
cluster of Serratia marcescens ATCC 274 (Sma 274), the representative strain of S. marcescens. We 
also discuss the potential applications of bacterial prodigiosins as a clinical drug and review current 
approaches to scale-up its synthesis, either in S. marcescens or using surrogate hosts and its purification 
from the expression hosts. Finally, a synthetic biology platform is proposed for a safer and more cost-
effective large-scale synthesis of prodigiosin in Escherichia coli. 
 
Prodigiosin 
Prodigiosin is a red linear tripyrrole molecule (Fig. 1A) made up of 3 rings, A, B and C. The A and B 
rings are connected in a bipyrrole unit whereas the B and C rings are joined in a dipyrrin (Jolicoeur and 
Lubell 2008). The pyrrole moiety (C ring) is linked to the methoxy bipyrrole (A and B rings) by a 
methylene bridge (Garneau-Tsodikova et al. 2006). The nomenclature for prodigiosin is 2-methyl-3-
amyl-6-methoxyprodigiosene (Roy et al. 2014) and prodigiosin secreted by Sma 274 has a molecular 
weight of 323.4 Dalton (Da) (Casullo de Araujo et al. 2010) with a chemical formula of C20H25N3O 
(Song et al. 2006). 
 
Prodigiosin is a hydrophobic molecule with a log Poctanol-water value of 5.16 (Suryawanshi et al. 
2016) and has a 4-methoxypyrollic core with a cationic charge at physiological pH that enables 
selective binding to alternating DNA sequences without discriminating between the AT and CG sites. 
Interestingly, prodigiosin is a monoprotonated ligand that binds to important anions such as Cl- and 
HCO3- and transports these ions via an antiport (OH-/Cl-) mechanism (Seganish and Davis 2005) or an 
H+/Cl- symport mechanism which alters the transmembrane pH gradient. Furthermore, the close 
proximity of the three pyrroles enables prodigiosin to bind to metal ions such as Cu2+ (Park et al. 2003) 
whereby a prodigiosin-Cu2+ complex facilitates double-strand DNA oxidative cleavage (Kimyon et al. 
2016; Melvin et al. 2000). The colour intensity of prodigiosin decreases when illuminated with light, 
suggesting that it is light-sensitive (Wang et al. 2012a). A subsequent report demonstrated that 
prodigiosin absorbs light and causes phototoxicity of the S. marcescens cytomembrane leading to 
leakage of prodigiosin (Wang et al. 2013).  
 
Prodigiosin can be extracted using acidic or alkaline solvents. Under acidic conditions, purified 
prodigiosin appears red in colour whilst pure prodigiosin in an alkaline solution has a yellow 
appearance. It can be detected by liquid chromatography-mass spectrophotometry (LC-MS) 
(Williamson et al. 2006b). The red prodigiosin is usually detectable at a maximum of 535 nm (Casullo 
de Araujo et al. 2010) but may present as an additional peak at 500 nm which corresponds to the native 
prodigiosin-protein complex (Andreyeva and Ogorodnikova 2015). On the other hand, the yellow 
pigment which is attributed to the formation of β-carotene in S. marcescens (Wang et al. 2012a) is 
visualised as a sharp spectral peak at 470 nm. Prodigiosin has a pKa value of 7.2 (Drink et al. 2015) 
and an Rf value of 0.59 (Lapenda et al. 2014).  
 
 The amount of prodigiosin produced can be estimated using the formula developed by Haddix 
and Wenner (2000) as shown below: 
 
Prodigiosin unit/cell = 
([OD499 – (1.381 × OD620)]) × 1000 
OD620
 
 
Where, OD499 = pigment absorption 
OD620 = bacterial culture absorption 
1.381 = constant 
 
This formula has since become the most commonly used method to quantify prodigiosin (Kamble and 
Hirawale 2012). 
 
 The physiological role of bacterial prodigiosin in vivo remains undefined. A number of reports 
have suggested potential functions that may provide an advantage in competition with other organisms 
(Gulani et al. 2012; ) and the continuously challenging natural environment (Stankovic et al. 2014) as 
well as increased surface hydrophobicity to facilitate ecological dispersion of the bacteria (Song et al. 
2006). This is in agreement with previous findings that environmental S. marcescens strains are 
normally pigmented whereas the non-pigmented strains are associated with nosocomial infections 
(Mahlen 2011). Although the role of prodigiosin still remains vague, the synthesis of this pigment is 
undoubtedly important to S. marcescens since a gene cluster of 20 kb is solely dedicated to its 
production.  
 
Biosynthesis of prodigiosin 
The pig cluster is comprised of 14 genes and has a size of 20,960 bp. In Sma 274, these genes are 
arranged in the order of pigA, pigB, pigC, pigD, pigE, pigF, pigG, pigH, pigI, pigJ, pigK, pigL, pigM 
and pigN (Fig. 2) (Harris et al. 2004) and the function of each protein is listed in Table 1. 
 
The pig genes in Sma 274 are flanked by the cueR and copA genes (Harris et al. 2004). The gene 
cueR is located 488 bp upstream of the start of the pig cluster whereas a gap of 183 bp separates copA 
and pigN (Harris et al. 2004; Venil et al. 2009). The gap of 183 bp between copA and pigN suggests 
that the expression of copA is independent of the pig gene cluster in Sma 274. A promoter for copA 
was predicted within this gap as well as a terminator that terminates the transcription of all the 14 pig 
genes. (Harris et al. 2004) (Fig. 2). From our analysis using the BPROM (Softberry) software 
(Solovyev and Salamov 2011), this promoter most likely serves as a binding site for a number of 
transcriptional factors such as arginine repressor 2 (argR2), fis protein, RNA polymerase sigma factor 
15 (rpoD15), repressor protein lexA, C-reactive protein (crp) and integration host factor (ihf) (Yip, 
unpublished). In Sma 274, a bifurcated pathway is needed to synthesise two key intermediates, namely 
2-methyl-3-n-amylpyrrole (MAP) and 4-methoxy-2,2’-bipyrrole-5-carbaldehyde (MBC) to produce 
prodigiosin (Harris et al. 2004; Williamson et al. 2006a; Williamson et al. 2006b).  
 
Fig.2 The genetic organisation of the prodigiosin biosynthetic gene cluster of Sma 274. Black 
block arrows indicate genes involved in the biosynthesis of the monopyrrole moiety, 2-
methyl-3-n-amylpyrrole (MAP) whereas white block arrows represent genes involved in 
synthesising the bipyrrole moiety, 4-methoxy-2,2’-bipyrrole-5-carbaldehyde (MBC). The 
arrow shaded with vertical lines is the gene that encodes for the terminal condensing 
enzyme, PigC. Transcriptional regulators of prodigiosin expression are indicated by 
arrows shaded with horizontal lines. (a) predicted promoter (Harris et al. 2004), (b) 
putative transcriptional terminator and (c) predicted copA promoter in Sma 274 (Harris et 
al. 2004). The -10 and -35 regions are in bold and underlined (Adapted from Harris et al. 
2004). 
 
 Twelve out of the 14 genes in the pig cluster have previously been assigned and characterised 
(Table 1) based on cross-feeding experiments of individual gene mutants (Williamson et al. 2005). 
Genes pigB, pigD and pigE were assigned to the synthesis of the monopyrrole moiety, MAP whereas 
pigA, pigF, pigG, pigH, pigI, pigJ, pigM and pigN are involved in the production of the bipyrrole 
moiety, MBC. The gene pigC encodes for the terminal condensing enzyme that condenses both MAP 
and MBC to produce prodigiosin. PigC has N- and C-terminal domains that share sequence similarities 
to phosphoryl transferase domains and the ATP-binding domain of a pyruvate phosphate dikinase, 
respectively (Harris et al. 2004). A BLASTP analysis indicated that both PigC and pyruvate phosphate 
dikinase of S. marcescens have the pyruvate phosphate dikinase PEP/pyruvate binding domain with 99% 
identity. This enzyme has a core catalytic region that binds MBC and MAP together to form 
prodigiosin (Williamson et al. 2006b). The functions of the gene products of pigK and pigL are 
currently not known but PigK may act as a molecular chaperone to assist folding of other Pig enzymes 
in the biosynthesis of MBC. In addition, PigL, which is a 4’-phosphopantetheinyl transferase, could be 
involved in the phosphopantetheinylation reaction in the MBC pathway (Williamson et al. 2005). An 
over view of prodigiosin biosynthesis is illustrated in Figure 3. 
 
Table 1 Function of each Pig protein involved in the biosynthesis of prodigiosin (Adapted from 
Williamson et al. 2005) 
 
Fig. 3 The bifurcated pathway of prodigiosin biosynthesis (Adapted from Williamson et al. 
2006b). 
 
Is prodigiosin suitable as a clinical drug? 
Production of microbial secondary metabolites has always been associated with the survival of the 
producing organisms (Figueiredo et al. 2008). Prodigiosin was evaluated through various studies and 
shown to have many beneficial properties that make it a promising drug candidate. 
 
Anticancer drug  
Prodigiosin is proposed to have an anti-cancer effect where it up-regulates p73 that restores the 
p53 signalling pathway in SW480 cancer cells and subsequently induces apoptosis of these cells. Since 
cancer cells carry a variety of mutated p53 with different hotspot mutations in the DNA-binding 
domain, these p53 mutants can interact with p73 and inhibit the rescue of the p53 pathway. 
Interestingly, prodigiosin is capable of disrupting this mutant p53/p73 interaction, suggesting that it can 
be used to treat cancer regardless of the status of p53 (Hong et al. 2014). Additionally, Kavitha et al. 
(2010) found that prodigiosin induces apoptotic cell death in HeLa cells in a dose-dependent manner 
with a half maximal inhibitory concentration (IC50) of 700 nM. Hong et al. (2014) demonstrated that 
prodigiosin selectively kills cancer cells and leaves normal cells unharmed at a low concentration range 
of 100 nM – 1 µM. This finding is in agreement with the previous study conducted by Montaner et al. 
(2000) that prodigiosin only induced apoptosis in haematopoietic cancer cells but leaves non-malignant 
cells unharmed. It has also been shown that prodigiosin acts independently on cancerous cells that 
express multidrug resistance transporter proteins such as multidrug resistance 1 (MDR1), breast cancer 
resistance protein (BCRP) and multidrug resistance-associated protein (MRP) transporters (Elahian et 
al. 2013).  
 
The preferential killing of cancer cells by prodigiosin can be attributed to its nature as an anion 
carrier. As an anion transporter, prodigiosin binds to biologically important anions such as Cl- and 
HCO3- to form a lipophilic prodigiosin-anion complex that can deacidify the pH of certain organelles 
such as lysosome, endosomes and Golgi apparatus by inhibiting V-ATPase via H+/Cl- symport 
mechanism. (Davis 2010). The altered transmembrane pH gradient causes the pH of the cellular 
environment of the cancer cells to decrease. Since the intracellular pH of cancer cells is more alkaline 
than that of normal cells, prodigiosin-treated cancer cells become more acidic, and therefore, undergo 
apoptosis (Nakashima et al. 2005). 
 
A synthetic prodigiosin derivative, obatoclax mesylate (GX15-070 or simply known as obatoclax) 
was discovered by Gemin X Pharmaceuticals Inc. (Canada) and has been used as an experimental drug 
on various types of cancers (Neidle 2013). Obatoclax was used in phase I clinical trials to treat 
advanced chronic lymphocytic leukaemia (O’ Brien et al. 2009). Additionally, it binds to the 
hydrophobic pocket of BH3 in Bcl-2 proteins, antagonises MCL-1 and initiates apoptosis in cancer 
cells (Urtishak et al. 2013). Obatoclax also helps to overcome glucocorticoid resistance (common in 
many chemotherapy protocols) in acute lymphoblastic leukaemia (Heidari et al. 2010) whilst showing 
promise in patients with small cell lung cancer when used in the combination with carboplatin-
epotoside (Chiappori et al. 2012). 
 
Antibacterial drug 
In general, cyclic molecules demonstrate distinct antibacterial activity compared to linear molecules 
(Lee et al. 2011). Kamble and Hiwarale (2012) proposed three mechanisms of prodigiosin as a potent 
antimicrobial agent: cleavage of bacterial DNA, cell cycle inhibition and modulation of pH. 
Prodigiosin has been demonstrated to exhibit antagonistic effects towards Staphylococcus aureus, 
Bacillus cereus (Gulani et al. 2012), Acinetobacter anitratus, Agrobacterium tumefaciens, Bacillus 
licheniformis, B. subtilis, B. thuringiensis, Erwinia sp., E. coli, Micrococcus sp., Methicillin-resistant 
Staphylococcus aureus (MRSA), S. epidermidis, S. saprophyticus (Ibrahim et al. 2014), Streptococcus 
pyogenes, Enterobacter faecalis and oxacillin-resistant S. aureus (ORSA) (Lapenda et al. 2014).  
 
Prodigiosin is inhibitory towards Borrelia burgdorferi, a pathogenic bacterium responsible for 
Lyme disease. B. burgdorferi are resistant to doxycycline or amoxicillin whilst prodigiosin had a low 
minimum inhibitory concentration of < 0.2 µg/mL and 24% activity against stationary phase and 
actively growing B. burgdorferi (Feng et al. 2015). A recent study conducted by Darshan and 
Manonmani (2016) showed that prodigiosin from S. nematodiphila induces programmed cell death 
(PCD) of B. cereus, Pseudomonas aeruginosa, S. aureus and E. coli as well as inhibits B. cereus and E. 
coli motility. Recently, it has been suggested that chaotropicity-mediated stress is the primary mode-of-
action for prodigiosin’s antimicrobial activity. The main target site for prodigiosin is the bacterial 
plasma membrane. As a chaotropic stressor, prodigiosin disrupts the bacterial plasma membrane and 
induces loss of essential intracellular substances such as sugars, amino acids, proteins and K+ ions from 
prodigiosin-treated bacteria (Suryawanshi et al. 2016). Collectively, these findings show that 
prodigiosin is a potential broad spectrum antibacterial agent. 
 
Antimalarial   
Prodigiosin exhibits antagonistic effects on the causative agent of malaria, Plasmodium falciparum 
(Castro 1967). Papireddy et al. (2011) reported that prodigiosin is antimalarial towards P. falciparum 
D6 (chloroquine-sensitive) and Dd2 (multidrug-resistant) strains, both in vitro and in vivo. An 
important finding by Patil et al. (2011) revealed that prodigiosin has larvicidal activity against the P. 
falciparum vectors: Aedes aegypti and Anopheles stephensi. Hence, prodigiosin is not only a potential 
candidate for post-infection treatment but also to eradicate the carriers of this parasite. Synthetic 
prodigiosins generated using alkyl or aryl substituents show remarkable reduction of P. falciparum in 
mice without compromising the health of the infected mice (Papireddy et al. 2011). 
 
Anti-mycotic agent 
Prodigiosin also inhibits the growth of many pathogenic fungi such as the filamentous fungi 
Cryptococcus sp. and Candida parapsilosis (Gulani et al. 2012), C. albicans, Aspergillus niger, 
Penicillium glaucum (Shaikh 2016) and Didymella applanata (Duzhak et al. 2012). Prodigiosin was 
more potent than Amphotericin B in impeding the growth of A. niger, Trichoderma viridae, 
Trichophyton rubrum and Trichophyton mentagrophytes (Sumathi et al. 2014).  
 
Prodigiosin does not play a role in bacterial pathogenesis 
In light of the beneficial properties of prodigiosin, it is imperative to determine if prodigiosin 
contributes to the virulence of S. marcescens and if it is safe to be administered for human therapy. 
Carbonell et al. (2000) had initially reported that pigmented S. marcescens strains cause infections 
much less frequently than non-pigmented strains, thus reducing any potential risk of infection during 
mass production of pigment.  
 
As RpoS sigma factor plays an important role in bacterial pathogenesis and stress response (Dong 
and Schellhorn 2010), its role in regulating prodigiosin production was investigated (Wilft and 
Salmond 2012). The rpoS mRNA contains an inhibitory stem-loop region that is altered by the binding 
of Hfq-dependent RprA which exposes the ribosome binding site for the translation of RpoS (σS). 
RpoS ( σ S) then represses transcription of the pig cluster. When Caenorhabditis elegans were 
challenged with Serratia rpoS mutant strains, prodigiosin production by the rpoS mutants increased but 
the mutants were attenuated in C. elegans, suggesting that prodigiosin is not vital for bacterial 
pathogenesis (Wilft and Salmond 2012). Recently, Seah et al. (2016) also reported that the mean time-
to-death of C. elegans challenged with pigmented and non-pigmented S. marcescens does not differ 
significantly suggesting that prodigiosin is non-toxic towards C. elegans. In a parallel study, silkworm 
larvae were treated with purified prodigiosin. The median lethal dose (LD50) for larvae injected with 
prodigiosin did not differ significantly from the control (untreated) larvae confirming that prodigiosin 
is not an essential virulence factor of entomopathogenic S. marcescens strains (Zhou et al. 2016). 
Suryawanshi and co-workers (2016) also suggested that prodigiosin is not a secreted toxin. These 
findings validate that prodigiosin is an innocuous metabolite that does not play a significant role in the 
pathogenesis of its native host.  
 
High-level production of prodigiosin from S. marcescens 
As reviewed above, prodigiosin has a number of potential applications as a therapeutic drug. However, 
a full clinical evaluation of the efficacy and safety of administering prodigiosin to patients is necessary 
and this would require large-scale production of prodigiosin. Therefore, parameters such as media 
composition and pH, temperature and incubation period have been extensively studied for high-level 
prodigiosin production from its natural host. 
 
Media composition 
Many types of differential and selective media have been developed for the isolation and confirmation 
of Serratia. Liquid media previously used for prodigiosin biosynthesis include nutrient broth (Haddix 
and Werner 2000), peptone glycerol broth (Montaner et al. 2000) and production medium (Bae et al. 
2001). Peptone glycerol broth supports higher prodigiosin production compared to nutrient broth and 
other synthetic media such as Luria-Bertani (LB), tryptone soy, tryptone yeast extract, yeast malt 
extract and glycerol extract broth (Gulani et al. 2012) whereby the addition of glycerol is essential for 
high production of prodigiosin (Chang et al. 2011). 
 
To lower the costs of prodigiosin production, many studies have been conducted using cheap and 
easily available substrates. The addition of 0.4% (w/v) ram horn peptone in control medium (yeast 
extract and mannitol) led to the production of 0.28 mg/mL prodigiosin by the S. marcescens MO-1 
strain (Kurbanoglu et al. 2015). Prodigiosin production levels of 38.75 mg/mL and 16.68 mg/mL were 
reported when peanut seed broth and powdered sesame seed broth were used, respectively (Giri et al. 
2004). The enhanced pigment production in peanut seed broth and sesame seed broth is due to the high 
fatty acid content in the media. Fatty acids promote cell growth and subsequently, higher pigment 
production (Chang et al. 2011). Saturated fatty acids are responsible for hyperpigmentation of S. 
marcescens because the saturated fatty acid content is relatively high in peanut seed broth compared to 
sesame seed broth. The role of unsaturated fatty acids is insignificant because growth in media 
containing peanut oil or sesame oil resulted in lower prodigiosin concentrations (Giri et al. 2004). The 
presence of fatty acids in the medium also yields 2-octenal (Spiteller et al. 2001), the precursor of the 
MAP biosynthesis pathway (Williamson et al. 2005), thereby, enhancing prodigiosin production. When 
cassava mannitol medium supplemented with 2% maltose was used as the culture medium, S. 
marcescens prodigiosin production levels of 49.5 mg/mL were recorded (Casullo de Araujo et al. 2010). 
Recently, Elkenawy and co-workers used crude glycerol with the addition of 1% (w/v) peptone and 109 
cells/mL inoculum size for high production of prodigiosin (870 units/cell) from S. marcescens MN5 
(Elkenawy et al. 2017). The presence of maltose, as an additional carbon source in nutrient broth has 
been shown to favour prodigiosin production compared to other carbon sources such as glucose (Giri et 
al. 2004), sucrose, mannitol, lactose, fructose and glucose in peptone glycerol broth (Gulani et al. 2012). 
Moreover, glucose was found to inhibit prodigiosin production in S. marcescens (Fender et al. 2012).  
 
pH of media 
Pigment synthesis is also inhibited at high pH (Fender et al. 2012). Prodigiosin production occurs when 
S. marcescens is grown in a pH range of 4 to 10 (Raj et al. 2009) but not at pH 3 and higher than pH 10 
(Wang et al. 2012b). Prodigiosin biosynthesis has been reported to be optimum at pH 7.0 - 8.5 
(Lapenda et al. 2014; Ramani et al. 2014).  
 
Temperature 
Maximum synthesis of prodigiosin was consistently recorded at temperatures between 22°C - 30°C 
(Elkenawy et al. 2017, Lapenda et al. 2014). PigC, the terminal-condensing enzyme in the bifurcated 
pathway, is significantly affected by temperature and reduced pigment biosynthesis is well documented 
at higher temperatures (Giri et al. 2004; Gulani et al. 2012). Temperatures > 30°C denature PigC, 
leaving MAP and MBC moieties uncondensed and no red pigment formation occurs. At temperatures < 
22°C, the lack of pigment formation is due to low PigC enzyme activity. Interestingly, pigment 
production is restored when there is a shift from a higher temperature (37°C) to a lower temperature 
(30°C) (Haddix and Wenner 2000) most likely a result of the renaturation of PigC which restores its 
enzymatic activity.  
 
Incubation period 
Generally, higher pigment production is observed after extended incubation periods as prodigiosin is a 
secondary metabolite produced during the stationary phase of bacterial growth (Elkenawy et al. 2017). 
Nonetheless, the incubation period for pigmentation in S. marcescens is strain-dependent and ranges 
from 36 hours (Giri et al. 2004) to 96 hours (Ramani et al. 2014). High prodigiosin synthesis was also 
reported after 144 hours (6 days) of incubation (Elkenawy et al. 2017). This unusually long incubation 
period is attributed to the low temperature (22°C) which delays the accumulation of sufficient S. 
marcescens cell biomass to synthesise prodigiosin.  
 
Scale-up production of prodigiosin from S. marcescens  
Production of prodigiosin is generally undertaken on a small scale and this is not cost effective due to 
the low levels of in vivo expression by S. marcescens and costly downstream purification. More 
recently, production of S. marcescens prodigiosin in culture was scaled-up in a study by Chen et al. 
(2013). They reported that production of prodigiosin increased from 2.3 mg/mL to 15.6 mg/mL when 
starch and peptone were utilised as carbon and nitrogen sources, respectively. The six-fold increase in 
pigment synthesis was attributed to a 6:4 starch:peptone ratio and supplementation with 0.56 mM 
FeSO4·4H2O, 3.25 mM MnSO4·4H2O and immobilisation of S. marcescens onto 3% calcium alginate 
beads. In addition, El-Bialy and El-Nour (2015) increased prodigiosin synthesis from an ethyl 
methanesulfonate (EMS) generated mutant of S. marcescens. Prodigiosin synthesis by the EMS-variant 
strain was eight-fold higher (658 ± 46.0 mg/L) compared to the parent strain (88.4 ± 4.4 mg/L) and the 
metabolite from the mutant strain was stable at alkaline pH and 80°C (El-Bialy and El-Nour 2015). 
 
Large-scale synthesis of prodigiosin using a synthetic biology approach 
High-level synthesis of prodigiosin directly from its original host incurs high costs whilst large-scale 
cultivation of S. marcescens is generally not regarded as safe. Although clinical strains are normally 
non-pigmented (Mahlen 2011), comparative genome analyses of pigmented and non-pigmented strains 
indicate that the genome content of both strains is highly conserved (Li et al. 2015) and thus, the use of 
large-scale S. marcescens culture for prodigiosin synthesis is not encouraged. The high production 
costs are attributed to the longer incubation period required for S. marcescens to synthesise prodigiosin 
(Elkenawy et al. 2017; Kamble and Hirawale 2012). To overcome these drawbacks, prodigiosin could 
be synthesised using a synthetic biology approach. Synthetic biology is a recent platform technology 
that enables high-level production of proteins and metabolites from DNA constructs. This can be 
achieved by transferring the related pathway from the original host into an industrial compliant host. 
This would enable safe and cost-effective synthesis of the desired product in large quantities. This 
approach provides a convenient platform to engineer complex biological systems for the production of 
food, drugs, polymers, fuels and biomass (Haseloff and Ajioka 2009). Using this approach, useful 
products such as the precursor to the antimalarial artemisinin (Keasling 2008), terpenoids (Chang et al. 
2007) and green biofuels (Atsumi et al. 2008) were successfully synthesised in high quantities. 
 
The availability of the Registry of Standard Biological Parts (http://partsregistry.org) and 
BioBricks Foundation (http://bbf.openwetware.org), provides a platform for using and sharing of 
standardised synthetic parts such as promoters, ribosome binding sites and terminators (Haseloff and 
Ajioka 2009). This platform allows easy selection of regulators for the overexpression of desired 
products from any DNA construct. Also, engineered microbial hosts and gene assembly techniques 
such as Gibson Assembly (Gibson et al. 2009) and Golden Gate Assembly (Engler et al. 2008) have 
enabled the development of more efficient and robust systems for use in this discipline. To enable easy 
selection of methods to build large DNA constructs, different DNA assembly techniques for synthetic 
biology applications have recently been reviewed (Juhas and Ajioka 2016a). 
 
 Several research teams have integrated the synthetic biology approach for the production of 
prodigiosin. The prodigiosin of H. chejuensis was successfully expressed in E. coli by Kwon et al. 
(2010). The main focus of their study was to identify the positive regulators that upregulate the 
biosynthesising hap cluster (prodigiosin gene cluster in H. chejuensis) and understand the biosynthetic 
pathways of prodigiosin. Although this study did not report increased pigment production in E. coli, 
this research outcome will be useful for future studies to overexpress prodigiosin in the heterologous 
host, E. coli, as well as in H. chejuensis (Kwon et al. 2010). Domrose et al. (2015) reported the 
synthesis of recombinant S. marcescens prodigiosin in Pseudomonas putida KT2440. In this work, 
random insertion of the pig cluster by transposition into the chromosome of P. putida was performed 
and generated a constitutive prodigiosin-producing P. putida strain. The standard parameters for the 
growth of P. putida were improved using Terrific Broth (TB) under high aeration at 20°C and 48 hours 
incubation. Under these conditions, the heterologous host was able to synthesise up to 14 ± 1 mg/g dry 
cell weight (DCW) of recombinant prodigiosin (Domrose et al. 2015). 
 
 High undecylprodigiosin production was also reported in its non-pathogenic native host S. 
coelicolor using a synthetic biology approach. The production of undecylprodigiosin in S. coelicolor 
M145 increased five times compared to that of the wild-type strain using the ɸBT1 and ɸC31 integrase 
strategy. This simple and straightforward strategy utilises the ɸBT1 integrase-mediated multisite 
recombination to delete part of the calcium-dependent antibiotic (CDA) and actinorhodin (ACT) 
biosynthesising gene clusters. The absence of endogenous gene clusters overexpressed 
undecylprodigiosin synthesis suggesting that the CDA, ACT and undecylprodigiosin biosynthesising 
(red) gene clusters compete for common precursors (Zhang et al. 2013). An enhanced 
undecylprodigiosin-producing S. coelicolor strain was recently developed by Liu et al. (2017). In their 
work, they inactivated the repressor gene, ohkA, and adopted the same approach as Zhang et al. (2013) 
which was to delete both the CDA and ACT gene clusters. Then, three copies of the red cluster were 
integrated into the chromosome of S. coelicolor and results showed that the developed strain had a 12-
fold increase in undecylprodigiosin production (96.8 mg/g DCW) relative to the wild-type strain S. 
coelicolor M-145 (Liu et al. 2017). 
 
Isolation and Purification of Prodigiosin from S. marcescens 
Prodigiosin is normally extracted from S. marcescens cultures using acidic (Williamson et al. 2006b) or 
basic solvents (Darshan and Manonmani 2016). Recently, Khanam and Chandra (2018) reported higher 
yield of prodigiosin was obtained using acidic extraction compared to alkaline extraction, with 
Methanol being a preferred solvent (Chen et al. 2018). This is due to acid hydrolysis that breaks down 
the bacterial cell wall and lipid bonds, thereby, enhancing the release of prodigiosin from S. 
marcescens (Khanam and Chandra 2018). Prodigiosin is also insoluble in water but soluble in organic 
solvents such as acetone (Sun et al. 2015), methylene chloride, dioxane, pyridine, chloroform, hexane 
and methanol (Juang and Yeh 2014). During acidic extraction, S. marcescens is pelleted, and 
resuspended in methanol. The bacterial suspension is homogenised, centrifuged and the organic portion 
is filtered through a 0.2 µm filter paper before concentrating. The crude product is then resuspended in 
methanol before purification by column chromatography (Chen et al. 2018). Both Dozie-Nwachukwu 
et al. (2017) and Chen et al. (2018) used silica gel as the stationary phase for adsorption and hexane as 
the mobile phase to elute pure prodigiosin. The eluate was then dried at 45°C to obtain pure prodigiosin 
in powder form (Chen et al. 2018). 
 
In an earlier report, Sun et al. (2015) extracted prodigiosin from dried S. marcescens jx1 cells 
using ultrasound-assisted extraction (with acetone as the extraction solvent) optimised by response 
surface methodology (RSM). Results from the RSM suggested that prodigiosin extraction is optimal at 
23.4°C using a solvent-to-solute ratio of 1:27.2 over an extraction period of 17.5 minutes. From their 
findings, 4.3 ± 0.02 g of prodigiosin was harvested from 100 g of dried cells (Sun et al. 2015). 
However, extraction and purification of prodigiosin are limiting factors in large-scale synthesis of 
prodigiosin. These downstream processes using organic solvents are costly and energy consuming 
(Arivizhivendhan et al. 2016), making downstream processing of prodigiosin not feasible which 
prevents the production of sufficient quantities of pure prodigiosin for clinical evaluation. Furthermore, 
the organic solvents used for prodigiosin extraction and purification are carcinogenic, making them an 
occupational hazard (Campo et al. 2013).  
 
To overcome these limitations, Arivizhivendhan et al. (2016) imparted a quaternary amine group 
onto iron oxide, Fe3O4 to become functionalised Fe3O4 ([Fe3O4]F) that increased the adsorption 
efficiency of prodigiosin. Using this method, efficiency of prodigiosin extraction was as high as 98% 
whilst the use of organic solvent was reduced by 95%. Khanam and Chandran (2018) reported that 
ultrasonication gave the highest yield of prodigiosin (2.54 ± 0.41 mg/mL) from 50 mg of dried S. 
marcescens biomass compared to other extraction methods when the following pipeline was used: heat 
treatment (60°C), 0.1 N HCl, 96% ethanol, homogenisation, and freezing and thawing.  
 
To increase the yield of extracted and purified prodigiosin, high-level prodigiosin synthesis in the 
producing host requires increasing the production of key products in the biosynthetic pathway. You et 
al. (2018) optimised the production of the key limiting enzyme in the pathway, PigC, in E. coli using 
RSM (optimal synthesis parameters were 0.73 g/L glucose, 13.17 g/L yeast extract and 5.86 g/L lactose 
in auto-induction medium). The extracted PigC had an optimal activity of 179.3 U/mL (You et al. 
2018). We suggest that the extracted PigC (You et al. 2018) could be added to a co-culture of two S. 
marcescens mutant strains (each mutant producing either MAP or MBC ((Chen et al. 2018)) to obtain 
higher yield of extracted and purified prodigiosin.  
 
 
 
Prospective Direction for the Synthesis of Prodigiosin 
Future work on prodigiosin production will shift from the traditional method of optimising the standard 
growth conditions of its native host to high-level pigment synthesis in a surrogate as well as non-
pathogenic native host using the synthetic biology approach. Previously, prodigiosin was successfully 
expressed in P. putida (Domrose et al. 2015) and S. coelicolor (Liu et al. 2017). Since prodigiosin 
possesses pharmaceutical value, large-scale synthesis of prodigiosin is required for full clinical 
evaluation. However, S. coelicolor and P. putida are not suitable hosts to be used in the synthesis of 
prodigiosin at industrial scale. The pig cluster of S. marcescens can be expressed in a safer and more 
industrial-compliant recombinant host such as E. coli.  
 
E. coli was used as a synthetic biology chassis for the successful production of artemisinin 
(Keasling 2008), biofuels (Atsumi et al. 2008) and terpenoids (Chang et al. 2007). Expression of 
prodigiosin in E. coli was attempted by Dauenhauer et al. (1984) but was not successful. The 
unsuccessful heterologous synthesis of prodigiosin in E. coli could be due to the use of an incomplete 
pig cluster (Dauenhauer et al. 1984) or inefficient protein expression of the gene cluster in E. coli. To 
enable high recombinant synthesis of prodigiosin in E. coli, the pig genes should be codon optimised 
based on the codon bias of E. coli. Recently, we (Yip et al. 2018) developed a codon optimisation 
strategy that improved recombinant protein synthesis in E. coli without negatively affecting the growth 
rate of the expression host. This strategy is suitable to be applied to any gene of interest for 
heterologous production in E. coli. Refactoring the gene cluster by codon optimisation and grouping 
the genes into synthetic operons under the control of well-characterised genetic parts available in the 
BioBricks Registry could promote heterologous prodigiosin synthesis in E. coli.  
 
The pig cluster is large (~20 kb) and recombinant DNA normally causes high metabolic burden 
and requires constant selective pressure (Cunningham et al. 2009) in a surrogate host. Nonetheless, 
current methods in synthetic biology allow for the integration of large synthetic DNA fragments into 
bacterial chromosomes for protein expression in E. coli (Juhas et al. 2014; Juhas and Ajioka 2015a; 
Juhas and Ajioka 2015b) and B. subtilis (Juhas and Ajioka 2016b). Recently, we also identified the E. 
coli motA flagellar gene as a suitable chromosomal integration site for synthetic DNA (Yip et al., in 
press). E. coli has greater potential to be developed as a synthetic biology chassis for the biosynthesis 
of prodigiosin compared to B. subtilis. This is because prodigiosin is antimicrobial towards Bacillus 
species by inducing autolysins in actively growing B. subtilis and other Bacillus species (Danevčič et 
al. 2016b). On the other hand, studies have reported that prodigiosin is not inhibitory towards E. coli 
(Danevčič et al. 2016a; Lapenda et al. 2015). With these approaches, prodigiosin synthesis using E. 
coli as a chassis may surpass the highest production obtained using S. marcescens cultures. The overall 
synthetic biology approach for the recombinant synthesis of prodigiosin in E. coli is summarised in Fig. 
4. 
 
Fig. 4 Synthetic biology approach for the synthesis of prodigiosin in a safer and more industrial-
compliant host, E. coli. A) The genes in the pig cluster are codon optimised based on the 
codon bias of E. coli and refactored according to the function of each gene product in 
prodigiosin biosynthesis. B) The gene cluster is refactored into three sub-clusters, namely 
MAP, MBC and pigC operon. In each operon, well-characterised synthetic parts such as 
promoter, ribosome binding site and terminator are incorporated to regulate gene 
expression. The genes arrangement in each operon is based on the order of the enzymes in 
the bifurcated pathway. In MBC operon, pigK and pigL are removed from the refactored 
cluster because they are not directly involved in the MBC synthesis. C) The three 
synthetic operons are then introduced into E. coli and successful expression of each 
operon enables production of prodigiosin in E. coli. 
 
Conclusion  
The beneficial properties of prodigiosin highlight the potential of this secondary metabolite as a clinical 
drug. This has prompted many research teams to study its biosynthesising gene cluster, elucidate its 
bifurcated pathways and optimise the standard growth parameters of S. marcescens to achieve high 
pigment production. Large-scale bacterial cultivation of the human pathogen S. marcescens is not 
encouraged as it is generally not considered as safe. With a thorough understanding on how prodigiosin 
is produced in S. marcescens, scientists can tap into the information for application using a synthetic 
biology approach. This would allow for cost-effective and safe large-scale synthesis of prodigiosin for 
a full clinical evaluation of its biological effects.  
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Table 1 Function of each Pig protein involved in the biosynthesis of prodigiosin (Adapted from 
Williamson et al. 2005) 
 
Protein Pathway Function 
PigA MBC L-prolyl-PCP dehydrogenase 
PigB MAP H2MAP dehydrogenase 
PigC Condensing Condensing enzyme 
PigD MAP 2-Acetyloctanal synthase 
PigE MAP 2-Acetyloctanal aminotransferase 
PigF MBC HBC O-methyl transferase 
PigG MBC Peptidyl carrier protein 
PigH MBC HBM synthase 
PigI MBC L-prolyl-AMP ligase 
PigJ MBC Pyrrolyl-β-ketoacyl ACP synthase 
PigK MBC Specific function unknown but may act as molecular chaperone to 
other Pig enzymes in protein folding 
PigL MBC 4’-Phosphopantetheinyl transferase 
PigM MBC HBM dehydrogenase 
PigN MBC Specific function unknown but is believed to methylate HBC to MBC 
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Abstract 14 
Prodigiosin, a red linear tripyrrole pigment and a member of the prodiginine family, is normally secreted by 15 
the human pathogen Serratia marcescens as a secondary metabolite. Studies on prodigiosin have received 16 
renewed attention as a result of reported immunosuppressive, antimicrobial and anticancer properties. 17 
High-level synthesis of prodigiosin and the bioengineering of strains to synthesise useful prodiginine 18 
derivatives have also been a subject of investigation. To exploit the potential use of prodigiosin as a clinical 19 
drug targeting bacteria or as a dye for textiles, high-level synthesis of prodigiosin is a prerequisite. This 20 
review presents an overview on the biosynthesis of prodigiosin from its natural host Serratia marcescens 21 
and through recombinant approaches as well as highlighting the beneficial properties of prodigiosin. We 22 
also discuss the prospect of adopting a synthetic biology approach for safe and cost-effective production of 23 
prodigiosin in a more industrially compliant surrogate host. 24 
 25 
Introduction 26 
Prodigiosin is a red bacterial pigment that is secreted as a secondary metabolite. It is the most prominent 27 
member of the prodiginine family (other members include undecylprodigiosin, cycloprodigiosin, 28 
metacycloprodigiosin, prodigiosin R1 and streptorubin B) (Fig. 1) (Stankovic et al. 2014). Prodigiosin has 29 
long been a subject of research interest due to its many potential beneficial properties that include 30 
anticancer (Elahian et al. 2013), antimicrobial (Ibrahim et al. 2014) and antimalarial (Papireddy et al. 2011) 31 
properties. This metabolite is secreted by a number of microorganisms such as Hahella chejuensis (Kim et 32 
al. 2006), Streptomyces coelicolor (Do and Nguyen 2014), Streptomyces grisiovirides (Kawasaki et al. 33 
2008), Serratia nematodiphila (Darshan and Manonmani 2016), Serratia rubidae (Siva et al. 2011) and 34 
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Serratia marcescens (Casullo de Araujo et al. 2010). Driven by the potential development and application 1 
of prodigiosin as a clinical drug, many studies have been undertaken to dissect its biosynthetic pathways as 2 
a means to increase production of this pigment. Nevertheless, attempts to develop prodigiosin as a 3 
therapeutic molecule have been hampered by reports of toxicity on eukaryotic cells (Pandey et al. 2009), its 4 
ability to intercalate and cause double stranded DNA breaks (Kimyon et al. 2016) as well as cell cycle 5 
arrest (Soto-Cerrato et al. 2007). Furthermore, purified prodigiosin is reportedly immunosuppressive on the 6 
human immune response (Liu and Nizet 2009). Taken together, prodigiosin was presumed to be cytotoxic 7 
towards eukaryotic cells and therefore, not suitable to be developed as a clinical drug. 8 
 9 
Fig.1 Members of the prodiginine family. A) prodigiosin B) undecylprodigiosin C) 10 
cycloprodigiosin D) metacycloprodigiosin E) prodigiosin R1 and F) streptorubin B 11 
(Adapted from PubChem (Kim et al. 2016)). 12 
 13 
 Nevertheless, recent studies have shown that prodigiosin is not genotoxic (Guryanov et al. 2013). 14 
Furthermore, bacterial prodigiosins and their synthetic derivatives are effective pro-apoptotic agents against 15 
various cancer cell lines where multiple cellular targets include multi-drug resistant cells with little or no 16 
toxicity towards normal cell lines (Elahian et al. 2013; Kavitha et al. 2010). These findings pave the way 17 
for prodigiosin to be developed as a promising drug candidate and efficient production of this microbial 18 
pigment is the prerequisite to its full clinical evaluation. However, large bacterial cultivation of S. 19 
marcescens for high prodigiosin production is not safe and there are limited reports on the expression of 20 
prodigiosin in a safer heterologous host for high-level synthesis.  21 
 22 
Hence, this review focuses on the organisation of the prodigiosin biosynthesising or pigment (pig) 23 
cluster of Serratia marcescens ATCC 274 (Sma 274), the representative strain of S. marcescens. We also 24 
discuss the potential applications of bacterial prodigiosins as a clinical drug and review current approaches 25 
to scale-up its synthesis, either in S. marcescens or using surrogate hosts and its purification from the 26 
expression hosts. Finally, a synthetic biology platform is proposed for a safer and more cost-effective 27 
large-scale synthesis of prodigiosin in Escherichia coli. 28 
 29 
Prodigiosin 30 
Prodigiosin is a red linear tripyrrole molecule (Fig. 1A) made up of 3 rings, A, B and C. The A and B rings 31 
are connected in a bipyrrole unit whereas the B and C rings are joined in a dipyrrin (Jolicoeur and Lubell 32 
2008). The pyrrole moiety (C ring) is linked to the methoxy bipyrrole (A and B rings) by a methylene 33 
bridge (Garneau-Tsodikova et al. 2006). The nomenclature for prodigiosin is 34 
2-methyl-3-amyl-6-methoxyprodigiosene (Roy et al. 2014) and prodigiosin secreted by Sma 274 has a 35 
molecular weight of 323.4 Dalton (Da) (Casullo de Araujo et al. 2010) with a chemical formula of 36 
C20H25N3O (Song et al. 2006). 37 
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 1 
Prodigiosin is a hydrophobic molecule with a log Poctanol-water value of 5.16 (Suryawanshi et al. 2016) 2 
and has a 4-methoxypyrollic core with a cationic charge at physiological pH that enables selective binding 3 
to alternating DNA sequences without discriminating between the AT and CG sites. Interestingly, 4 
prodigiosin is a monoprotonated ligand that binds to important anions such as Cl- and HCO3- and transports 5 
these ions via an antiport (OH-/Cl-) mechanism (Seganish and Davis 2005) or an H+/Cl- symport mechanism 6 
which alters the transmembrane pH gradient. Furthermore, the close proximity of the three pyrroles enables 7 
prodigiosin to bind to metal ions such as Cu2+ (Park et al. 2003) whereby a prodigiosin-Cu2+ complex 8 
facilitates double-strand DNA oxidative cleavage (Kimyon et al. 2016; Melvin et al. 2000). The colour 9 
intensity of prodigiosin decreases when illuminated with light, suggesting that it is light-sensitive (Wang et 10 
al. 2012a). A subsequent report demonstrated that prodigiosin absorbs light and causes phototoxicity of the 11 
S. marcescens cytomembrane leading to leakage of prodigiosin (Wang et al. 2013).  12 
 13 
Prodigiosin can be extracted using acidic or alkaline solvents. Under acidic conditions, purified 14 
prodigiosin appears red in colour whilst pure prodigiosin in an alkaline solution has a yellow appearance. It 15 
can be detected by liquid chromatography-mass spectrophotometry (LC-MS) (Williamson et al. 2006b). 16 
The red prodigiosin is usually detectable at a maximum of 535 nm (Casullo de Araujo et al. 2010) but may 17 
present as an additional peak at 500 nm which corresponds to the native prodigiosin-protein complex 18 
(Andreyeva and Ogorodnikova 2015). On the other hand, the yellow pigment which is attributed to the 19 
formation of β-carotene in S. marcescens (Wang et al. 2012a) is visualised as a sharp spectral peak at 470 20 
nm. Prodigiosin has a pKa value of 7.2 (Drink et al. 2015) and an Rf value of 0.59 (Lapenda et al. 2014).  21 
 22 
 The amount of prodigiosin produced can be estimated using the formula developed by Haddix and 23 
Wenner (2000) as shown below: 24 
 25 
Prodigiosin unit/cell = 
([OD499 – (1.381 × OD620)]) × 1000 
OD620
 26 
 27 
Where, OD499 = pigment absorption 28 
OD620 = bacterial culture absorption 29 
1.381 = constant 30 
 31 
This formula has since become the most commonly used method to quantify prodigiosin (Kamble and 32 
Hirawale 2012). 33 
 34 
 The physiological role of bacterial prodigiosin in vivo remains undefined. A number of reports have 35 
suggested potential functions that may provide an advantage in competition with other organisms (Gulani et 36 
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al. 2012; ) and the continuously challenging natural environment (Stankovic et al. 2014) as well as 1 
increased surface hydrophobicity to facilitate ecological dispersion of the bacteria (Song et al. 2006). This 2 
is in agreement with previous findings that environmental S. marcescens strains are normally pigmented 3 
whereas the non-pigmented strains are associated with nosocomial infections (Mahlen 2011). Although the 4 
role of prodigiosin still remains vague, the synthesis of this pigment is undoubtedly important to S. 5 
marcescens since a gene cluster of 20 kb is solely dedicated to its production.  6 
 7 
Biosynthesis of prodigiosin 8 
The pig cluster is comprised of 14 genes and has a size of 20,960 bp. In Sma 274, these genes are arranged 9 
in the order of pigA, pigB, pigC, pigD, pigE, pigF, pigG, pigH, pigI, pigJ, pigK, pigL, pigM and pigN (Fig. 10 
2) (Harris et al. 2004) and the function of each protein is listed in Table 1. 11 
 12 
The pig genes in Sma 274 are flanked by the cueR and copA genes (Harris et al. 2004). The gene cueR 13 
is located 488 bp upstream of the start of the pig cluster whereas a gap of 183 bp separates copA and pigN 14 
(Harris et al. 2004; Venil et al. 2009). The gap of 183 bp between copA and pigN suggests that the 15 
expression of copA is independent of the pig gene cluster in Sma 274. A promoter for copA was predicted 16 
within this gap as well as a terminator that terminates the transcription of all the 14 pig genes. (Harris et al. 17 
2004) (Fig. 2). From our analysis using the BPROM (Softberry) software (Solovyev and Salamov 2011), 18 
this promoter most likely serves as a binding site for a number of transcriptional factors such as arginine 19 
repressor 2 (argR2), fis protein, RNA polymerase sigma factor 15 (rpoD15), repressor protein lexA, 20 
C-reactive protein (crp) and integration host factor (ihf) (Yip, unpublished). In Sma 274, a bifurcated 21 
pathway is needed to synthesise two key intermediates, namely 2-methyl-3-n-amylpyrrole (MAP) and 22 
4-methoxy-2,2’-bipyrrole-5-carbaldehyde (MBC) to produce prodigiosin (Harris et al. 2004; Williamson et 23 
al. 2006a; Williamson et al. 2006b).  24 
 25 
Fig.2 The genetic organisation of the prodigiosin biosynthetic gene cluster of Sma 274. Black block 26 
arrows indicate genes involved in the biosynthesis of the monopyrrole moiety, 27 
2-methyl-3-n-amylpyrrole (MAP) whereas white block arrows represent genes involved in 28 
synthesising the bipyrrole moiety, 4-methoxy-2,2’-bipyrrole-5-carbaldehyde (MBC). The 29 
arrow shaded with vertical lines is the gene that encodes for the terminal condensing enzyme, 30 
PigC. Transcriptional regulators of prodigiosin expression are indicated by arrows shaded 31 
with horizontal lines. (a) predicted promoter (Harris et al. 2004), (b) putative transcriptional 32 
terminator and (c) predicted copA promoter in Sma 274 (Harris et al. 2004). The -10 and -35 33 
regions are in bold and underlined (Adapted from Harris et al. 2004). 34 
 35 
 Twelve out of the 14 genes in the pig cluster have previously been assigned and characterised (Table 1) 36 
based on cross-feeding experiments of individual gene mutants (Williamson et al. 2005). Genes pigB, pigD 37 
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and pigE were assigned to the synthesis of the monopyrrole moiety, MAP whereas pigA, pigF, pigG, pigH, 1 
pigI, pigJ, pigM and pigN are involved in the production of the bipyrrole moiety, MBC. The gene pigC 2 
encodes for the terminal condensing enzyme that condenses both MAP and MBC to produce prodigiosin. 3 
PigC has N- and C-terminal domains that share sequence similarities to phosphoryl transferase domains and 4 
the ATP-binding domain of a pyruvate phosphate dikinase, respectively (Harris et al. 2004). A BLASTP 5 
analysis indicated that both PigC and pyruvate phosphate dikinase of S. marcescens have the pyruvate 6 
phosphate dikinase PEP/pyruvate binding domain with 99% identity. This enzyme has a core catalytic 7 
region that binds MBC and MAP together to form prodigiosin (Williamson et al. 2006b). The functions of 8 
the gene products of pigK and pigL are currently not known but PigK may act as a molecular chaperone to 9 
assist folding of other Pig enzymes in the biosynthesis of MBC. In addition, PigL, which is a 10 
4’-phosphopantetheinyl transferase, could be involved in the phosphopantetheinylation reaction in the 11 
MBC pathway (Williamson et al. 2005). An over view of prodigiosin biosynthesis is illustrated in Figure 3. 12 
 13 
Table 1 Function of each Pig protein involved in the biosynthesis of prodigiosin (Adapted from 14 
Williamson et al. 2005) 15 
 16 
Fig. 3 The bifurcated pathway of prodigiosin biosynthesis (Adapted from Williamson et al. 2006b). 17 
 18 
Is prodigiosin suitable as a clinical drug? 19 
Production of microbial secondary metabolites has always been associated with the survival of the 20 
producing organisms (Figueiredo et al. 2008). Prodigiosin was evaluated through various studies and shown 21 
to have many beneficial properties that make it a promising drug candidate. 22 
 23 
Anticancer drug  24 
Prodigiosin is proposed to have an anti-cancer effect where it up-regulates p73 that restores the p53 25 
signalling pathway in SW480 cancer cells and subsequently induces apoptosis of these cells. Since cancer 26 
cells carry a variety of mutated p53 with different hotspot mutations in the DNA-binding domain, these p53 27 
mutants can interact with p73 and inhibit the rescue of the p53 pathway. Interestingly, prodigiosin is 28 
capable of disrupting this mutant p53/p73 interaction, suggesting that it can be used to treat cancer 29 
regardless of the status of p53 (Hong et al. 2014). Additionally, Kavitha et al. (2010) found that prodigiosin 30 
induces apoptotic cell death in HeLa cells in a dose-dependent manner with a half maximal inhibitory 31 
concentration (IC50) of 700 nM. Hong et al. (2014) demonstrated that prodigiosin selectively kills cancer 32 
cells and leaves normal cells unharmed at a low concentration range of 100 nM – 1 µM. This finding is in 33 
agreement with the previous study conducted by Montaner et al. (2000) that prodigiosin only induced 34 
apoptosis in haematopoietic cancer cells but leaves non-malignant cells unharmed. It has also been shown 35 
that prodigiosin acts independently on cancerous cells that express multidrug resistance transporter proteins 36 
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such as multidrug resistance 1 (MDR1), breast cancer resistance protein (BCRP) and multidrug 1 
resistance-associated protein (MRP) transporters (Elahian et al. 2013).  2 
 3 
The preferential killing of cancer cells by prodigiosin can be attributed to its nature as an anion carrier. 4 
As an anion transporter, prodigiosin binds to biologically important anions such as Cl- and HCO3- to form a 5 
lipophilic prodigiosin-anion complex that can deacidify the pH of certain organelles such as lysosome, 6 
endosomes and Golgi apparatus by inhibiting V-ATPase via H+/Cl- symport mechanism. (Davis 2010). The 7 
altered transmembrane pH gradient causes the pH of the cellular environment of the cancer cells to decrease. 8 
Since the intracellular pH of cancer cells is more alkaline than that of normal cells, prodigiosin-treated 9 
cancer cells become more acidic, and therefore, undergo apoptosis (Nakashima et al. 2005). 10 
 11 
A synthetic prodigiosin derivative, obatoclax mesylate (GX15-070 or simply known as obatoclax) was 12 
discovered by Gemin X Pharmaceuticals Inc. (Canada) and has been used as an experimental drug on 13 
various types of cancers (Neidle 2013). Obatoclax was used in phase I clinical trials to treat advanced 14 
chronic lymphocytic leukaemia (O’ Brien et al. 2009). Additionally, it binds to the hydrophobic pocket of 15 
BH3 in Bcl-2 proteins, antagonises MCL-1 and initiates apoptosis in cancer cells (Urtishak et al. 2013). 16 
Obatoclax also helps to overcome glucocorticoid resistance (common in many chemotherapy protocols) in 17 
acute lymphoblastic leukaemia (Heidari et al. 2010) whilst showing promise in patients with small cell lung 18 
cancer when used in the combination with carboplatin-epotoside (Chiappori et al. 2012). 19 
 20 
Antibacterial drug 21 
In general, cyclic molecules demonstrate distinct antibacterial activity compared to linear molecules (Lee et 22 
al. 2011). Kamble and Hiwarale (2012) proposed three mechanisms of prodigiosin as a potent antimicrobial 23 
agent: cleavage of bacterial DNA, cell cycle inhibition and modulation of pH. Prodigiosin has been 24 
demonstrated to exhibit antagonistic effects towards Staphylococcus aureus, Bacillus cereus (Gulani et al. 25 
2012), Acinetobacter anitratus, Agrobacterium tumefaciens, Bacillus licheniformis, B. subtilis, B. 26 
thuringiensis, Erwinia sp., E. coli, Micrococcus sp., Methicillin-resistant Staphylococcus aureus (MRSA), S. 27 
epidermidis, S. saprophyticus (Ibrahim et al. 2014), Streptococcus pyogenes, Enterobacter faecalis and 28 
oxacillin-resistant S. aureus (ORSA) (Lapenda et al. 2014).  29 
 30 
Prodigiosin is inhibitory towards Borrelia burgdorferi, a pathogenic bacterium responsible for Lyme 31 
disease. B. burgdorferi are resistant to doxycycline or amoxicillin whilst prodigiosin had a low minimum 32 
inhibitory concentration of < 0.2 µg/mL and 24% activity against stationary phase and actively growing B. 33 
burgdorferi (Feng et al. 2015). A recent study conducted by Darshan and Manonmani (2016) showed that 34 
prodigiosin from S. nematodiphila induces programmed cell death (PCD) of B. cereus, Pseudomonas 35 
aeruginosa, S. aureus and E. coli as well as inhibits B. cereus and E. coli motility. Recently, it has been 36 
suggested that chaotropicity-mediated stress is the primary mode-of-action for prodigiosin’s antimicrobial 37 
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activity. The main target site for prodigiosin is the bacterial plasma membrane. As a chaotropic stressor, 1 
prodigiosin disrupts the bacterial plasma membrane and induces loss of essential intracellular substances 2 
such as sugars, amino acids, proteins and K+ ions from prodigiosin-treated bacteria (Suryawanshi et al. 3 
2016). Collectively, these findings show that prodigiosin is a potential broad spectrum antibacterial agent. 4 
 5 
Antimalarial   6 
Prodigiosin exhibits antagonistic effects on the causative agent of malaria, Plasmodium falciparum (Castro 7 
1967). Papireddy et al. (2011) reported that prodigiosin is antimalarial towards P. falciparum D6 8 
(chloroquine-sensitive) and Dd2 (multidrug-resistant) strains, both in vitro and in vivo. An important 9 
finding by Patil et al. (2011) revealed that prodigiosin has larvicidal activity against the P. falciparum 10 
vectors: Aedes aegypti and Anopheles stephensi. Hence, prodigiosin is not only a potential candidate for 11 
post-infection treatment but also to eradicate the carriers of this parasite. Synthetic prodigiosins generated 12 
using alkyl or aryl substituents show remarkable reduction of P. falciparum in mice without compromising 13 
the health of the infected mice (Papireddy et al. 2011). 14 
 15 
Anti-mycotic agent 16 
Prodigiosin also inhibits the growth of many pathogenic fungi such as the filamentous fungi Cryptococcus 17 
sp. and Candida parapsilosis (Gulani et al. 2012), C. albicans, Aspergillus niger, Penicillium glaucum 18 
(Shaikh 2016) and Didymella applanata (Duzhak et al. 2012). Prodigiosin was more potent than 19 
Amphotericin B in impeding the growth of A. niger, Trichoderma viridae, Trichophyton rubrum and 20 
Trichophyton mentagrophytes (Sumathi et al. 2014).  21 
 22 
Prodigiosin does not play a role in bacterial pathogenesis 23 
In light of the beneficial properties of prodigiosin, it is imperative to determine if prodigiosin contributes to 24 
the virulence of S. marcescens and if it is safe to be administered for human therapy. Carbonell et al. (2000) 25 
had initially reported that pigmented S. marcescens strains cause infections much less frequently than 26 
non-pigmented strains, thus reducing any potential risk of infection during mass production of pigment.  27 
 28 
As RpoS sigma factor plays an important role in bacterial pathogenesis and stress response (Dong and 29 
Schellhorn 2010), its role in regulating prodigiosin production was investigated (Wilft and Salmond 2012). 30 
The rpoS mRNA contains an inhibitory stem-loop region that is altered by the binding of Hfq-dependent 31 
RprA which exposes the ribosome binding site for the translation of RpoS (σS). RpoS (σS) then represses 32 
transcription of the pig cluster. When Caenorhabditis elegans were challenged with Serratia rpoS mutant 33 
strains, prodigiosin production by the rpoS mutants increased but the mutants were attenuated in C. elegans, 34 
suggesting that prodigiosin is not vital for bacterial pathogenesis (Wilft and Salmond 2012). Recently, Seah 35 
et al. (2016) also reported that the mean time-to-death of C. elegans challenged with pigmented and 36 
non-pigmented S. marcescens does not differ significantly suggesting that prodigiosin is non-toxic towards 37 
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C. elegans. In a parallel study, silkworm larvae were treated with purified prodigiosin. The median lethal 1 
dose (LD50) for larvae injected with prodigiosin did not differ significantly from the control (untreated) 2 
larvae confirming that prodigiosin is not an essential virulence factor of entomopathogenic S. marcescens 3 
strains (Zhou et al. 2016). Suryawanshi and co-workers (2016) also suggested that prodigiosin is not a 4 
secreted toxin. These findings validate that prodigiosin is an innocuous metabolite that does not play a 5 
significant role in the pathogenesis of its native host.  6 
 7 
High-level production of prodigiosin from S. marcescens 8 
As reviewed above, prodigiosin has a number of potential applications as a therapeutic drug. However, a 9 
full clinical evaluation of the efficacy and safety of administering prodigiosin to patients is necessary and 10 
this would require large-scale production of prodigiosin. Therefore, parameters such as media composition 11 
and pH, temperature and incubation period have been extensively studied for high-level prodigiosin 12 
production from its natural host. 13 
 14 
Media composition 15 
Many types of differential and selective media have been developed for the isolation and confirmation of 16 
Serratia. Liquid media previously used for prodigiosin biosynthesis include nutrient broth (Haddix and 17 
Werner 2000), peptone glycerol broth (Montaner et al. 2000) and production medium (Bae et al. 2001). 18 
Peptone glycerol broth supports higher prodigiosin production compared to nutrient broth and other 19 
synthetic media such as Luria-Bertani (LB), tryptone soy, tryptone yeast extract, yeast malt extract and 20 
glycerol extract broth (Gulani et al. 2012) whereby the addition of glycerol is essential for high production 21 
of prodigiosin (Chang et al. 2011). 22 
 23 
To lower the costs of prodigiosin production, many studies have been conducted using cheap and 24 
easily available substrates. The addition of 0.4% (w/v) ram horn peptone in control medium (yeast extract 25 
and mannitol) led to the production of 0.28 mg/mL prodigiosin by the S. marcescens MO-1 strain 26 
(Kurbanoglu et al. 2015). Prodigiosin production levels of 38.75 mg/mL and 16.68 mg/mL were reported 27 
when peanut seed broth and powdered sesame seed broth were used, respectively (Giri et al. 2004). The 28 
enhanced pigment production in peanut seed broth and sesame seed broth is due to the high fatty acid 29 
content in the media. Fatty acids promote cell growth and subsequently, higher pigment production (Chang 30 
et al. 2011). Saturated fatty acids are responsible for hyperpigmentation of S. marcescens because the 31 
saturated fatty acid content is relatively high in peanut seed broth compared to sesame seed broth. The role 32 
of unsaturated fatty acids is insignificant because growth in media containing peanut oil or sesame oil 33 
resulted in lower prodigiosin concentrations (Giri et al. 2004). The presence of fatty acids in the medium 34 
also yields 2-octenal (Spiteller et al. 2001), the precursor of the MAP biosynthesis pathway (Williamson et 35 
al. 2005), thereby, enhancing prodigiosin production. When cassava mannitol medium supplemented with 2% 36 
maltose was used as the culture medium, S. marcescens prodigiosin production levels of 49.5 mg/mL were 37 
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recorded (Casullo de Araujo et al. 2010). Recently, Elkenawy and co-workers used crude glycerol with the 1 
addition of 1% (w/v) peptone and 109 cells/mL inoculum size for high production of prodigiosin (870 2 
units/cell) from S. marcescens MN5 (Elkenawy et al. 2017). The presence of maltose, as an additional 3 
carbon source in nutrient broth has been shown to favour prodigiosin production compared to other carbon 4 
sources such as glucose (Giri et al. 2004), sucrose, mannitol, lactose, fructose and glucose in peptone 5 
glycerol broth (Gulani et al. 2012). Moreover, glucose was found to inhibit prodigiosin production in S. 6 
marcescens (Fender et al. 2012).  7 
 8 
pH of media 9 
Pigment synthesis is also inhibited at high pH (Fender et al. 2012). Prodigiosin production occurs when S. 10 
marcescens is grown in a pH range of 4 to 10 (Raj et al. 2009) but not at pH 3 and higher than pH 10 11 
(Wang et al. 2012b). Prodigiosin biosynthesis has been reported to be optimum at pH 7.0 - 8.5 (Lapenda et 12 
al. 2014; Ramani et al. 2014).  13 
 14 
Temperature 15 
Maximum synthesis of prodigiosin was consistently recorded at temperatures between 22°C - 30°C 16 
(Elkenawy et al. 2017, Lapenda et al. 2014). PigC, the terminal-condensing enzyme in the bifurcated 17 
pathway, is significantly affected by temperature and reduced pigment biosynthesis is well documented at 18 
higher temperatures (Giri et al. 2004; Gulani et al. 2012). Temperatures > 30°C denature PigC, leaving 19 
MAP and MBC moieties uncondensed and no red pigment formation occurs. At temperatures < 22°C, the 20 
lack of pigment formation is due to low PigC enzyme activity. Interestingly, pigment production is restored 21 
when there is a shift from a higher temperature (37°C) to a lower temperature (30°C) (Haddix and Wenner 22 
2000) most likely a result of the renaturation of PigC which restores its enzymatic activity.  23 
 24 
Incubation period 25 
Generally, higher pigment production is observed after extended incubation periods as prodigiosin is a 26 
secondary metabolite produced during the stationary phase of bacterial growth (Elkenawy et al. 2017). 27 
Nonetheless, the incubation period for pigmentation in S. marcescens is strain-dependent and ranges from 28 
36 hours (Giri et al. 2004) to 96 hours (Ramani et al. 2014). High prodigiosin synthesis was also reported 29 
after 144 hours (6 days) of incubation (Elkenawy et al. 2017). This unusually long incubation period is 30 
attributed to the low temperature (22°C) which delays the accumulation of sufficient S. marcescens cell 31 
biomass to synthesise prodigiosin.  32 
 33 
Scale-up production of prodigiosin from S. marcescens  34 
Production of prodigiosin is generally undertaken on a small scale and this is not cost effective due to the 35 
low levels of in vivo expression by S. marcescens and costly downstream purification. More recently, 36 
production of S. marcescens prodigiosin in culture was scaled-up in a study by Chen et al. (2013). They 37 
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reported that production of prodigiosin increased from 2.3 mg/mL to 15.6 mg/mL when starch and peptone 1 
were utilised as carbon and nitrogen sources, respectively. The six-fold increase in pigment synthesis was 2 
attributed to a 6:4 starch:peptone ratio and supplementation with 0.56 mM FeSO4·4H2O, 3.25 mM 3 
MnSO4·4H2O and immobilisation of S. marcescens onto 3% calcium alginate beads. In addition, El-Bialy 4 
and El-Nour (2015) increased prodigiosin synthesis from an ethyl methanesulfonate (EMS) generated 5 
mutant of S. marcescens. Prodigiosin synthesis by the EMS-variant strain was eight-fold higher (658 ± 46.0 6 
mg/L) compared to the parent strain (88.4 ± 4.4 mg/L) and the metabolite from the mutant strain was stable 7 
at alkaline pH and 80°C (El-Bialy and El-Nour 2015). 8 
 9 
Large-scale synthesis of prodigiosin using a synthetic biology approach 10 
High-level synthesis of prodigiosin directly from its original host incurs high costs whilst large-scale 11 
cultivation of S. marcescens is generally not regarded as safe. Although clinical strains are normally 12 
non-pigmented (Mahlen 2011), comparative genome analyses of pigmented and non-pigmented strains 13 
indicate that the genome content of both strains is highly conserved (Li et al. 2015) and thus, the use of 14 
large-scale S. marcescens culture for prodigiosin synthesis is not encouraged. The high production costs are 15 
attributed to the longer incubation period required for S. marcescens to synthesise prodigiosin (Elkenawy et 16 
al. 2017; Kamble and Hirawale 2012). To overcome these drawbacks, prodigiosin could be synthesised 17 
using a synthetic biology approach. Synthetic biology is a recent platform technology that enables 18 
high-level production of proteins and metabolites from DNA constructs. This can be achieved by 19 
transferring the related pathway from the original host into an industrial compliant host. This would enable 20 
safe and cost-effective synthesis of the desired product in large quantities. This approach provides a 21 
convenient platform to engineer complex biological systems for the production of food, drugs, polymers, 22 
fuels and biomass (Haseloff and Ajioka 2009). Using this approach, useful products such as the precursor to 23 
the antimalarial artemisinin (Keasling 2008), terpenoids (Chang et al. 2007) and green biofuels (Atsumi et 24 
al. 2008) were successfully synthesised in high quantities. 25 
 26 
The availability of the Registry of Standard Biological Parts (http://partsregistry.org) and BioBricks 27 
Foundation (http://bbf.openwetware.org), provides a platform for using and sharing of standardised 28 
synthetic parts such as promoters, ribosome binding sites and terminators (Haseloff and Ajioka 2009). This 29 
platform allows easy selection of regulators for the overexpression of desired products from any DNA 30 
construct. Also, engineered microbial hosts and gene assembly techniques such as Gibson Assembly 31 
(Gibson et al. 2009) and Golden Gate Assembly (Engler et al. 2008) have enabled the development of more 32 
efficient and robust systems for use in this discipline. To enable easy selection of methods to build large 33 
DNA constructs, different DNA assembly techniques for synthetic biology applications have recently been 34 
reviewed (Juhas and Ajioka 2016a). 35 
 36 
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 Several research teams have integrated the synthetic biology approach for the production of 1 
prodigiosin. The prodigiosin of H. chejuensis was successfully expressed in E. coli by Kwon et al. (2010). 2 
The main focus of their study was to identify the positive regulators that upregulate the biosynthesising hap 3 
cluster (prodigiosin gene cluster in H. chejuensis) and understand the biosynthetic pathways of prodigiosin. 4 
Although this study did not report increased pigment production in E. coli, this research outcome will be 5 
useful for future studies to overexpress prodigiosin in the heterologous host, E. coli, as well as in H. 6 
chejuensis (Kwon et al. 2010). Domrose et al. (2015) reported the synthesis of recombinant S. marcescens 7 
prodigiosin in Pseudomonas putida KT2440. In this work, random insertion of the pig cluster by 8 
transposition into the chromosome of P. putida was performed and generated a constitutive 9 
prodigiosin-producing P. putida strain. The standard parameters for the growth of P. putida were improved 10 
using Terrific Broth (TB) under high aeration at 20°C and 48 hours incubation. Under these conditions, the 11 
heterologous host was able to synthesise up to 14 ± 1 mg/g dry cell weight (DCW) of recombinant 12 
prodigiosin (Domrose et al. 2015). 13 
 14 
 High undecylprodigiosin production was also reported in its non-pathogenic native host S. coelicolor 15 
using a synthetic biology approach. The production of undecylprodigiosin in S. coelicolor M145 increased 16 
five times compared to that of the wild-type strain using the ɸBT1 and ɸC31 integrase strategy. This simple 17 
and straightforward strategy utilises the ɸBT1 integrase-mediated multisite recombination to delete part of 18 
the calcium-dependent antibiotic (CDA) and actinorhodin (ACT) biosynthesising gene clusters. The 19 
absence of endogenous gene clusters overexpressed undecylprodigiosin synthesis suggesting that the CDA, 20 
ACT and undecylprodigiosin biosynthesising (red) gene clusters compete for common precursors (Zhang et 21 
al. 2013). An enhanced undecylprodigiosin-producing S. coelicolor strain was recently developed by Liu et 22 
al. (2017). In their work, they inactivated the repressor gene, ohkA, and adopted the same approach as 23 
Zhang et al. (2013) which was to delete both the CDA and ACT gene clusters. Then, three copies of the red 24 
cluster were integrated into the chromosome of S. coelicolor and results showed that the developed strain 25 
had a 12-fold increase in undecylprodigiosin production (96.8 mg/g DCW) relative to the wild-type strain S. 26 
coelicolor M-145 (Liu et al. 2017). 27 
 28 
Isolation and Purification of Prodigiosin from S. marcescens 29 
Prodigiosin is normally extracted from S. marcescens cultures using acidic (Williamson et al. 2006b) or 30 
basic solvents (Darshan and Manonmani 2016). Recently, Khanam and Chandra (2018) reported higher 31 
yield of prodigiosin was obtained using acidic extraction compared to alkaline extraction, with Methanol 32 
being a preferred solvent (Chen et al. 2018). This is due to acid hydrolysis that breaks down the bacterial 33 
cell wall and lipid bonds, thereby, enhancing the release of prodigiosin from S. marcescens (Khanam and 34 
Chandra 2018). Prodigiosin is also insoluble in water but soluble in organic solvents such as acetone (Sun 35 
et al. 2015), methylene chloride, dioxane, pyridine, chloroform, hexane and methanol (Juang and Yeh 36 
2014). During acidic extraction, S. marcescens is pelleted, and resuspended in methanol. The bacterial 37 
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suspension is homogenised, centrifuged and the organic portion is filtered through a 0.2 µm filter paper 1 
before concentrating. The crude product is then resuspended in methanol before purification by column 2 
chromatography (Chen et al. 2018). Both Dozie-Nwachukwu et al. (2017) and Chen et al. (2018) used silica 3 
gel as the stationary phase for adsorption and hexane as the mobile phase to elute pure prodigiosin. The 4 
eluate was then dried at 45°C to obtain pure prodigiosin in powder form (Chen et al. 2018). 5 
 6 
In an earlier report, Sun et al. (2015) extracted prodigiosin from dried S. marcescens jx1 cells using 7 
ultrasound-assisted extraction (with acetone as the extraction solvent) optimised by response surface 8 
methodology (RSM). Results from the RSM suggested that prodigiosin extraction is optimal at 23.4°C 9 
using a solvent-to-solute ratio of 1:27.2 over an extraction period of 17.5 minutes. From their findings, 4.3 10 
± 0.02 g of prodigiosin was harvested from 100 g of dried cells (Sun et al. 2015). However, extraction and 11 
purification of prodigiosin are limiting factors in large-scale synthesis of prodigiosin. These downstream 12 
processes using organic solvents are costly and energy consuming (Arivizhivendhan et al. 2016), making 13 
downstream processing of prodigiosin not feasible which prevents the production of sufficient quantities of 14 
pure prodigiosin for clinical evaluation. Furthermore, the organic solvents used for prodigiosin extraction 15 
and purification are carcinogenic, making them an occupational hazard (Campo et al. 2013).  16 
 17 
To overcome these limitations, Arivizhivendhan et al. (2016) imparted a quaternary amine group onto 18 
iron oxide, Fe3O4 to become functionalised Fe3O4 ([Fe3O4]F) that increased the adsorption efficiency of 19 
prodigiosin. Using this method, efficiency of prodigiosin extraction was as high as 98% whilst the use of 20 
organic solvent was reduced by 95%. Khanam and Chandran (2018) reported that ultrasonication gave the 21 
highest yield of prodigiosin (2.54 ± 0.41 mg/mL) from 50 mg of dried S. marcescens biomass compared to 22 
other extraction methods when the following pipeline was used: heat treatment (60°C), 0.1 N HCl, 96% 23 
ethanol, homogenisation, and freezing and thawing.  24 
 25 
To increase the yield of extracted and purified prodigiosin, high-level prodigiosin synthesis in the 26 
producing host requires increasing the production of key products in the biosynthetic pathway. You et al. 27 
(2018) optimised the production of the key limiting enzyme in the pathway, PigC, in E. coli using RSM 28 
(optimal synthesis parameters were 0.73 g/L glucose, 13.17 g/L yeast extract and 5.86 g/L lactose in 29 
auto-induction medium). The extracted PigC had an optimal activity of 179.3 U/mL (You et al. 2018). We 30 
suggest that the extracted PigC (You et al. 2018) could be added to a co-culture of two S. marcescens 31 
mutant strains (each mutant producing either MAP or MBC ((Chen et al. 2018)) to obtain higher yield of 32 
extracted and purified prodigiosin.  33 
 34 
 35 
 36 
Prospective Direction for the Synthesis of Prodigiosin 37 
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Future work on prodigiosin production will shift from the traditional method of optimising the standard 1 
growth conditions of its native host to high-level pigment synthesis in a surrogate as well as non-pathogenic 2 
native host using the synthetic biology approach. Previously, prodigiosin was successfully expressed in P. 3 
putida (Domrose et al. 2015) and S. coelicolor (Liu et al. 2017). Since prodigiosin possesses 4 
pharmaceutical value, large-scale synthesis of prodigiosin is required for full clinical evaluation. However, 5 
S. coelicolor and P. putida are not suitable hosts to be used in the synthesis of prodigiosin at industrial scale. 6 
The pig cluster of S. marcescens can be expressed in a safer and more industrial-compliant recombinant 7 
host such as E. coli.  8 
 9 
E. coli was used as a synthetic biology chassis for the successful production of artemisinin (Keasling 10 
2008), biofuels (Atsumi et al. 2008) and terpenoids (Chang et al. 2007). Expression of prodigiosin in E. coli 11 
was attempted by Dauenhauer et al. (1984) but was not successful. The unsuccessful heterologous synthesis 12 
of prodigiosin in E. coli could be due to the use of an incomplete pig cluster (Dauenhauer et al. 1984) or 13 
inefficient protein expression of the gene cluster in E. coli. To enable high recombinant synthesis of 14 
prodigiosin in E. coli, the pig genes should be codon optimised based on the codon bias of E. coli. Recently, 15 
we (Yip et al. 2018) developed a codon optimisation strategy that improved recombinant protein synthesis 16 
in E. coli without negatively affecting the growth rate of the expression host. This strategy is suitable to be 17 
applied to any gene of interest for heterologous production in E. coli. Refactoring the gene cluster by codon 18 
optimisation and grouping the genes into synthetic operons under the control of well-characterised genetic 19 
parts available in the BioBricks Registry could promote heterologous prodigiosin synthesis in E. coli.  20 
 21 
The pig cluster is large (~20 kb) and recombinant DNA normally causes high metabolic burden and 22 
requires constant selective pressure (Cunningham et al. 2009) in a surrogate host. Nonetheless, current 23 
methods in synthetic biology allow for the integration of large synthetic DNA fragments into bacterial 24 
chromosomes for protein expression in E. coli (Juhas et al. 2014; Juhas and Ajioka 2015a; Juhas and Ajioka 25 
2015b) and B. subtilis (Juhas and Ajioka 2016b). Recently, we also identified the E. coli motA flagellar 26 
gene as a suitable chromosomal integration site for synthetic DNA (Yip et al., in press). E. coli has greater 27 
potential to be developed as a synthetic biology chassis for the biosynthesis of prodigiosin compared to B. 28 
subtilis. This is because prodigiosin is antimicrobial towards Bacillus species by inducing autolysins in 29 
actively growing B. subtilis and other Bacillus species (Danevčič et al. 2016b). On the other hand, studies 30 
have reported that prodigiosin is not inhibitory towards E. coli (Danevčič et al. 2016a; Lapenda et al. 2015). 31 
With these approaches, prodigiosin synthesis using E. coli as a chassis may surpass the highest production 32 
obtained using S. marcescens cultures. The overall synthetic biology approach for the recombinant 33 
synthesis of prodigiosin in E. coli is summarised in Fig. 4. 34 
 35 
Fig. 4 Synthetic biology approach for the synthesis of prodigiosin in a safer and more 36 
industrial-compliant host, E. coli. A) The genes in the pig cluster are codon optimised based 37 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 14 
 
on the codon bias of E. coli and refactored according to the function of each gene product in 1 
prodigiosin biosynthesis. B) The gene cluster is refactored into three sub-clusters, namely 2 
MAP, MBC and pigC operon. In each operon, well-characterised synthetic parts such as 3 
promoter, ribosome binding site and terminator are incorporated to regulate gene expression. 4 
The genes arrangement in each operon is based on the order of the enzymes in the bifurcated 5 
pathway. In MBC operon, pigK and pigL are removed from the refactored cluster because 6 
they are not directly involved in the MBC synthesis. C) The three synthetic operons are then 7 
introduced into E. coli and successful expression of each operon enables production of 8 
prodigiosin in E. coli. 9 
 10 
Conclusion  11 
The beneficial properties of prodigiosin highlight the potential of this secondary metabolite as a clinical 12 
drug. This has prompted many research teams to study its biosynthesising gene cluster, elucidate its 13 
bifurcated pathways and optimise the standard growth parameters of S. marcescens to achieve high pigment 14 
production. Large-scale bacterial cultivation of the human pathogen S. marcescens is not encouraged as it is 15 
generally not considered as safe. With a thorough understanding on how prodigiosin is produced in S. 16 
marcescens, scientists can tap into the information for application using a synthetic biology approach. This 17 
would allow for cost-effective and safe large-scale synthesis of prodigiosin for a full clinical evaluation of 18 
its biological effects.  19 
 20 
Funding Information We gratefully acknowledge Universiti Kebangsaan Malaysia for the funding 21 
provided (grant number ICONIC-2013-004) that initiated this collaboration and the Commonwealth 22 
Scholarship Commission for supporting C.H. Yip through the Commonwealth Split-Site PhD Award 2015 23 
during his placement at Cambridge University. 24 
 25 
Ethical Statement This article does not contain any studies with human participants or animals performed 26 
by any of the authors. 27 
 28 
Conflict of Interest The authors declare that they have no conflict of interest. 29 
 30 
References 31 
Andreyeva IN, Ogorodnikova TI (2015) Pigmentation of Serratia marcescens and spectral properties of 32 
 prodigiosin. Mikrobiologiia 84:43-49. doi: 10.1134/S0026261715010026 33 
Atsumi S, Hanai T, Liao JC (2008) Non-fermentative pathways for synthesis of branched-chain higher 34 
 alcohols as biofuels. Nature 451: 86-89. doi: 10.1038/nature06450 35 
Arivizhivendhan KV, Mahesh M, Boopathy R, Sekaran G (2016) A novel method for the extraction of 36 
prodigiosin from bacterial fermenter integrated with sequential batch extraction reactor using 37 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 15 
 
magnetic iron oxide. Process Biochem 51:1731-1737. doi: 10.1016/j.procbio.2016.07.012 1 
Bae J, Moon H, Oh KK, Kim CH, Lee DS, Kim SW, Hong SI (2001) A novel bioreactor with an internal 2 
 adsorbent for integrated fermentation and recovery of prodigiosin-like pigment produced from 3 
 Serratia sp. KH-95. Biotechnol Lett 23:1315-1319. doi: 10.1023/A:10105734 4 
Campo P, Morata TC, Hong OS (2013) Chemical exposure and hearing loss. Dis Mon 59:119-138. doi: 5 
10.1016/j.disamonth.2013.01.003 6 
Castro AJ (1967) Antimalarial activity of prodigiosin. Nature 213:903-904. doi: 10.1038/213903a0 7 
Casullo de Araújo HW, Fukushima K, Campos-Takaki GM (2010) Prodigiosin production by Serratia 8 
marcescens UCP 1549 using renewable-resources as low-cost substrate. Molecules 9 
15:6931-6940.  doi: 10.3390/molecules15106931 10 
Carbonell GV, Della Colleta HHM, Yano T, Darini ALC, Levy CE, Fonseca BAL (2000) Clinical 11 
 relevance and virulence factors of pigmented Serratia marcescens. FEMS Immunol Med 12 
 Microbiol 28:143-149. doi: 1574-695X.2000.tb01469.x 13 
Chang CC, Chen WC, Ho SF, Wu HS, Wei YH (2011) Development of natural anti-tumor drugs by 14 
 microorganisms. J Biosci Bioeng 111:501–511. doi: 10.1016/j.jbiosc.2010.12.026 15 
Chang MCY, Eachus RA, Trieu W, Ro DK, Keasling JD (2007) Engineering Escherichia coli for the 16 
 production of functionalized terpenoids using plant P450s. Nat Chem Biol 3:274-277. doi: 17 
 10.1038/nchembio875 18 
Chen WC, Yu WJ, Chang CC, Chang JS, Huang SH, Chang CH, Chen SY, Chien CC, Yao CL, Chen WM, 19 
 Wei YH (2013) Enhancing production of prodigiosin from Serratia marcescens C3 by statistical 20 
 experiment design and porous carrier addition strategy. Biochem Eng J 78:93-100. doi: 21 
 10.1016/j.bej.2013.02.001 22 
Chen WC, Tsai MJ, Soo PC, Wang LF, Tsai SL, Chang YK, Wei YH (2018) Construction and 23 
co-cultivation of two mutant strains harboring key precursor genes to produce prodigiosin. J Biosci 24 
Bioeng 126:783-789. doi: 10.1016/j.jbiosc.2018.06.010 25 
Chiappori AA, Schreeder MT, Moezi MM, Stephenson JJ, Blakely J, Salgia R, Chu QS, Ross HJ (2012) A 26 
phase I trial of pan-Bcl-2 antagonist obatoclax administered as a 3-h or a 24-h infusion in combination 27 
with carboplatin and etoposide in patients with extensive-stage small cell lung cancer. Br J Cancer 28 
106: 839–845. doi: 10.1038/bjc.2012.21 29 
Cunningham DS, Koepsel RR, Ataai M,  Domach MM (2009) Factors affecting plasmid production in 30 
Escherichia coli from a resource allocation standpoint. Microb Cell Fact 8. 31 
doi:10.1186/1475-2859-8-27 32 
Danevčič T, Vezjak MB, Zorec M, Stopar D (2016a) Prodigiosin-a multifaceted Escherichia coli 33 
 antimicrobial agent. PLoS One 11. doi:10.1371/journal.pone.0162412 34 
Danevčič T, Vezjak MB, Tabor M, Zorec M, Stopar D (2016b) Prodigiosin induces autolysins in actively 35 
 grown Bacillus subtilis cells. Front Microbiol 7. doi:10.3389/fmicb.2016.00027 36 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 16 
 
Darshan N, Manonmani HK (2016) Prodigiosin inhibits motility and activates bacterial cell death revealing 1 
 molecular biomarkers of programmed cell death. AMB Express 6. doi:10.1186/s13568-016-0222-z 2 
Dauenhauer SA, Hull RA, Williams RP (1984) Cloning and expression in Escherichia coli of Serratia 3 
marcescens genes encoding prodigiosin biosynthesis. J Bacteriol. 158:1128-1132. 4 
Davis JT (2010) Anion binding and transport by prodigiosin and its analog. In: Gale P, Dehaen W (eds) 5 
 Anion Recognition in Supramolecular Chemistry. Topics in Heterocyclic Chemistry 24. Springer, 6 
 Berlin, Heidelberg, pp 145-176 7 
Do HNA, Nguyen THK (2014) Studies on the prodigiosin production from Streptomyces coelicolor in 8 
 liquid media by using heated Lactobacillus rhamnosus. J Appl Pharm Sci 4:21-24. doi: 9 
 10.7324/JAPS.2014.40504 10 
Domrose A, Klein AS, Hage-Huismann J, Thies S, Svensson V, Classen T, Pietruszka J, Jaegar K, Drepper 11 
 T Loeschcke A (2015) Efficient recombinant production of prodigiosin in Pseudomonas putida. Front 12 
 Microbiol 6. doi:10.3389/fmicb.2015.00972 13 
Dong T, Schellhorn HE (2010) Role of RpoS in virulence of pathogens. Infect Immun 78:887–897. doi: 14 
 10.1128/IAI.00882-09 15 
Dozie-Nwachukwu SO, Danyuo Y, Obayemi JD, Odusanya OS, Malatesta K, Soboyejo WO (2017) 16 
Extraction and encapsulation of prodigiosin in chitosan microsphere for targeted drug delivery. Mater 17 
Sci Eng C 71:268-278. doi: 10.1016/j.msec.2016.09.078 18 
Drink E, Dugourd P, Dumont E, Aronssohn N, Antoine R, Loison C (2015) Optical properties of 19 
 prodigiosin and obatoclax. Action spectroscopy and theorectical calculations. Phys Chem Chem Phys 20 
 17:25946-25955. doi: 10.1039/C5CP01498K 21 
Duzhak AB, Panfilova ZI, Duzhak TG, Vasyunina EA, Shternshis MV (2012) Role of prodigiosin and 22 
 chitinases in antagonistic activity of the bacterium Serratia marcescens against the fungus Didymella 23 
 applanata. Biochemistry 77:910-916. doi: 10.1134/S0006297912080123 24 
Elahian F, Moghimi B, Dinmohammadi F, Ghamghami M, Hamidi M, Mirzaei SA (2013) The anticancer 25 
 agent prodigiosin is not a multidrug resistance protein substrate. DNA Cell Biol. 32(3): 90-97. doi: 26 
 10.1089/dna.2012.1902 27 
El-Bialy HA, El-Nour SAA (2015) Physical and chemical stress on Serratia marcescens and studies on 28 
 prodigiosin production. Ann Microbiol 65:59-68. doi: 10.1007/s13213-014-0837-8 29 
Elkenawy NM, Yassin AS, Elhifnawy HN, Amin MA (2017) Optimization of prodigiosin production by 30 
 Serratia marcescens using crude glycerol and enhancing production using gamma radiation. 31 
 Biotechnol Rep 14:47-53. doi: 10.1016/j.btre.2017.04.001 32 
Engler C, Kandzia R, Marillonnet S (2008) A one pot, one step, precision cloning method with high 33 
throughput capability. PloS One 3. doi:10.1371/journal.pone.0003647 34 
Fender JE, Bender CM, Stella NA, Lahr RM, Kalivoda EJ, Shanks RMQ (2012) Serratia marcescens 35 
 quinoprotein glucose dehydrogenase activity mediates acidification and inhibition of prodigiosin 36 
 production by glucose. Appl Environ Microbiol 78:6225-6235. doi: 10.1128/AEM.01778-12 37 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 17 
 
Feng J, Shi W, Zhang S, Zhang Y (2015) Identification of new compounds with high activity against 1 
 stationary phase Borellia burgdorferi from the NCI compound collection. Emerg Microbes Infect 4. 2 
 doi:10.1038/emi.2015.31 3 
Figueiredo AC, Barroso JG, Pedro LG, Scheffer JJC (2008) Factors affecting secondary metabolite 4 
 production in plants: volatile components and essential oils. Flavour Fragr J 23:213-226. doi: 5 
 10.1002/ffj.1875 6 
Garneau-Tsodikova S, Dorrestein P, Kelleher NL, Walsh CT (2006) Protein assembly line components in 7 
 prodigiosin biosynthesis: Characterization of PigA, G, H, I, J. J Am Chem Soc 128:12600-12601. doi: 8 
 10.1021/ja063611l 9 
Gibson DG, Young L, Chuang RY, Venter JC, Hutchison III CA, Smith HO (2009) Enzymatic assembly of 10 
 DNA molecules up to several hundred kilobases. Nat Methods 6:343-345. doi: 10.1038/nmeth.1318 11 
Giri AV, Anandkumar N, Muthukumaran G, Pennathur G (2004) A novel medium for the enhanced cell 12 
 growth and production of prodigiosin from Serratia marcescens isolated from soil. BMC Microbiol 4. 13 
 doi:10.1186/1471-2180-4-11 14 
Gulani C, Bhattacharya S, Das A (2012) Assessment of process parameters influencing the enhanced 15 
 production of prodigiosin from Serratia marcescens and evaluation of its antimicrobial, antioxidant 16 
 and dyeing potential. Malays J Microbiol 8:116-122. doi: 10.21161/mjm.03612 17 
Guryanov ID, Karamova NS, Yusupova DV, Gnezdilov OI, Koshkarova LA (2013) Bacterial pigment 18 
 prodigiosin and its genotoxic effect. Bioorg Khim 39:106-111. doi: 19 
 10.1134/S1068162012060040 20 
Haddix PL, Werner TF (2000) Spectrophotometric assay of gene expression: Serratia marcescens 21 
 pigmentation. Bioscene 26:3-13 22 
Harris APK, Williamson NR, Slater H, Cox A, Abbasi S, Foulds I, Simonsen HT, Leeper FJ, Salmond GP 23 
 (2004) The Serratia gene cluster encoding biosynthesis of the red antibiotic, prodigiosin, shows 24 
 species- and strain-dependent genome context variation. Microbiology 150:3547-3560. doi: 25 
 10.1099/mic.0.27222-0 26 
Haseloff J, Ajioka J (2009) Synthetic biology: history, challenges and prospects. J R Soc Interface 27 
 6:S389-S391. doi: 10.1098/rsif.2009.0176.focus 28 
Heidari N, Hicks MA, Harada H (2010) GX15-070 (obatoclax) overcomes glucocorticoid resistance in 29 
 acute lymphoblastic leukemia through induction of apoptosis and autophagy. Cell Death Dis 1. 30 
 doi:10.1038/cddis.2010.53 31 
Hong B, Prabhu VV, Zhang S, van den Heuvel AP, Dicker DT, Kopelovich L, El-Deiry WS (2014) 32 
 Prodigiosin rescues deficient p53 signaling and anti-tumor effects via up-regulating p73 and disrupting 33 
 its interaction with mutant p53. Cancer Res 74:1153-1165. doi: 10.1158/0008-5472.CAN-13-0955 34 
Ibrahim D, Nazari TF, Kassim J, Lim SH (2014) Prodigiosin-an antibacterial red pigment produced by 35 
 Serratia marcescens IBRL USM 84 associated with a marine sponge Xestospongia testudinaria. J 36 
 Appl Pharm Sci 4:1-6. doi: 10.7324/JAPS.2014.40101 37 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 18 
 
Jolicoeur B, Lubell WD (2008) Prodigiosin synthesis with electron rich 2,2’-bipyrroles. Can J Chem 1 
 86:213-218. doi: 10.1139/v07-150 2 
Juang RS, Yeh CL (2014) Adsorptive recovery and purification of prodigiosin from methanol/water 3 
solutions of Serratia marcescens fermentation broth. Biotechnol Bioprocess Eng 19:159-168. doi: 4 
10.1007/s12257-013-0547-2 5 
Juhas M, Ajioka JW (2015a) Flagellar region 3b supports strong expression of integrated DNA and the 6 
 highest chromosomal integration efficiency of the Escherichia coli flagellar regions. Microb 7 
 Biotechnol 8:726-738. doi:  10.1111/1751-7915.12296 8 
Juhas M, Ajioka JW (2015b) Identification and validation of novel chromosomal integration and expression 9 
 loci in Escherichia coli flagellar region 1. PLoS One 10. doi:10.1371/journal.pone.0123007 10 
Juhas M, Ajioka JW (2016a) High molecular weight DNA assembly in vivo for synthetic biology 11 
 applications. Crit Rev Biotechnol 37. doi: 10.3109/07388551.2016.1141394 12 
Juhas M, Ajioka JW (2016b) Integrative bacterial artificial chromosomes for DNA integration into the 13 
 Bacillus subtilis chromosome. J Microbiol Methods 125:1-7. doi: 10.1016/j.mimet.2016.03.017 14 
Juhas M, Evans LDB, Frost J, Davenport PW, Yarkoni O, Gillian MF, Ajioka JW (2014) Escherichia coli 15 
 flagellar genes as target sites for integration and expression of genetic circuits. PLoS One 9. 16 
 doi:10.1371/journal.pone.0111451 17 
Kamble KD, Hiwarale VD (2012) Prodigiosin production from Serratia marcescens strain obtained from 18 
 farm soil. Int J Environ Sci 3:631-638. doi: 10.6088/ijes.2012030131061 19 
Kavitha R, Aiswariya S, Ratnavali CMG (2010) Anticancer activity of red pigment from Serratia 20 
marcescens in human cervix carcinoma. Int J Pharmtech Res 2:784–787 21 
Kawasaki T, Sakurai F, Hayakawa Y (2008) A prodigiosin from the roseophilin producer Streptomyces 22 
 griseoviridis. J Nat Prod 71:1265-1267. doi: 10.1021/np7007494 23 
Keasling JD (2008) Synthetic biology for synthetic chemistry. ACS Chem Biol 3:64-76. 24 
 doi: 10.1021/cb7002434 25 
Khanam B, Chandra R (2018) Comparative analysis of prodigiosin isolated from endophyte Serratia 26 
marcescens 66:194-201. doi: 10.1111/lam.12840 27 
Kim D, Park YK, Lee JS, Kim JF, Jeong H, Kim BS, Lee CH (2006) Analysis of a prodigiosin biosynthetic 28 
 gene cluster from the marine bacterium Hahella chejuensis KCTC 2396. J Microbiol Biotechnol 29 
 16:1912-1918 30 
Kim S, Thiessen PA, Bolton EE, Chen J, Fu G, Gindulyte A, Han L, He J, He S, Shoemaker BA, Wang J, 31 
Yu B, Zhang J, Bryant SH (2016) PubChem Substance and Compound databases. Nucleic Acids Res 32 
44. doi: 10.1093/nar/gkv951 33 
Kimyon O, Das T, Ibugo AI, Kutty SK, Ho KK, Tebben J, Kumar N, Manefield M (2016) Serratia 34 
 secondary metabolite prodigiosin inhibits Pseudomonas aeruginosa biofilm development by 35 
 producing reactive oxygen species that damage biological molecules. Front Microbiol 7. 36 
 doi:10.3389/fmicb.2016.00972 37 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 19 
 
Kurbanoglu EB, Ozdal M, Ozdal OG, Algur OF (2015) Enhanced production of of prodigiosin by Serratia 1 
marcescens MO-1 using ram horne peptone. Braz J Microbiol 46:631-637.  doi: 2 
10.1590/S1517-838246246220131143 3 
Kwon SK, Park YK, Kim JF (2010) Genome-wide screening and identification of factors affecting the 4 
 biosynthesis of prodigiosin by Hahella chejuensis, using Escherichia coli as a surrogate host. Appl 5 
 Environ Microbiol 76:1661-1668. doi: 10.1128/AEM.01468-09 6 
Lapenda JC, Maciel CCS, Xavier HS, Alves da Silva CA, Campos-Takaki CM (2014) Production and 7 
 toxicology evaluation of prodigiosin from Serratia marcescens UCP/WFCC1549 on mannitol solid 8 
 medium. Int J Appl Res Nat Prod 7:32-38 9 
Lapenda JC, Silva PA, Vicalvi MC, Sena KXFR, Nascimento SC (2015) Antimicrobial activity of 10 
 prodigiosin isolated from Serratia marcescens UFPEDA 398. World J Microbiol Biotechnol 31:399–11 
 406. doi: 10.1007/s11274-014-1793-y 12 
Lee JS, Kim YS, Park S, Kim J, Kang SJ, Lee MH, Ryu S, Choi JM, Oh TK, Yoon JH (2011) Exceptional 13 
 production of both prodigiosin and cycloprodigiosin as major metabolic constituents by a novel 14 
 marine bacterium, Zooshikella rubidus S1-1. Appl Environ Microbiol 77:4967-4973. doi: 15 
 10.1128/AEM.01986-10 16 
Li PP, Kwok AHY, Jiang JW, Ran TT, Xu DQ, Wang WW, Leung FC (2015) Comparative genome 17 
 analyses of Serratia marcescens FS14 reveals its high antagonistic potential. PLoS One 10. 18 
 doi:10.1371/journal.pone.0123061 19 
Liu GY, Nizet V (2009) Color me bad: microbial pigments as virulence factors. Trends Microbiol 20 
 17:406-413. doi:  10.1016/j.tim.2009.06.006 21 
Liu PP, Zhu H, Zheng GS, Jiang WH, Lu YH (2017) Metabolic engineering of Streptomyces coelicolor for 22 
 enhanced prodigiosins (RED) production. Sci China Life Sci 60: doi:10.1007/s11427-017-9117-x 23 
Mahlen SD (2011) Serratia infections: from military experiments to current practice. Clin Microbiol Rev 24 
 24:755-791. doi: 10.1128/CMR.00017-11 25 
Melvin MS, Tomlinson JT, Saluta GR, Kucera GL, Lindquist N, Manderville RA (2000) Double strand 26 
 DNA cleavage by copper-prodigiosin. J Am Chem Soc 122:6333-6334. doi: 10.1021/ja0000798 27 
Montaner B, Navarro S, Piqué M, Vilaseca M, Martinell M, Giralt E, Gil J, Perez-Tomas P (2000) 28 
 Prodigiosin from the supernatant of Serratia marcescens induces apoptosis in haematopoietic cancer 29 
 cell lines. Br J Pharmacol 131:585-593. doi: 10.1038/sj.bjp.0703614 30 
Nakashima T, Tamura T, Kurachi M, Yamaguchi K, Oda T (2005) Apoptosis-mediated cytotoxicity of 31 
 prodigiosin-like red pigments produced by gamma-Proteobacterium and its multiple bioactivities. Biol 32 
 Pharm Bull 28:2289-2295. doi: 10.1248/bpb.28.2289 33 
Neidle S (2013) Prodigiosin. In: Neidle S (ed). Cancer drug design and discovery. London: School of 34 
 Pharmacy, University College London, pp 104-105 35 
O’ Brien SM, Claxton DF, Crump M, Faderi S, Kipps T, Keating MJ, Viallet J, Cheson BD (2009) Phase I 36 
study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients 37 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 20 
 
with advanced chronic lymphocytic leukemia. Blood 113:299-305. doi: 1 
 10.1182/blood-2008-02-137943 2 
Pandey R, Chander R, Sainis KB (2009) Prodigiosins as anticancer agents: living upto their name. Curr 3 
 Pharm Des 15: 732-741. doi: 10.2174/138161209787582192 4 
Papireddy K, Smilkstein M, Kelly JX, Salem SM, Alhamadsheh M, Haynes SW, Challis GL, Reynolds KA 5 
 (2011) Antimalarial activity of natural and synthetic prodiginines. J Med Chem 54:5296-5306. 6 
 doi:  10.1021/jm200543y 7 
Park G, Tomlinson JT, Melvin MS, Wright MW, Day CS, Manderville RA (2003) Zinc and copper 8 
 complexes of prodigiosin: implications for copper-mediated double-strand DNA cleavage. Org Lett 9 
 5:113-116. doi: 10.1021/ol027165s 10 
Patil CD, Patil SV, Salunke BK, Salunkhe RB (2011) Prodigiosin produced by Serratia marcescens 11 
 NMCC46 as a mosquito larvicidal agent against Aedes aegypti and Anopheles stephensi. Parasitol Res 12 
 109:1179-1187. doi: 10.1007/s00436-011-2365-9 13 
Raj DN, Dhanasekaran D, Thajuddin N, Panneerselvam A (2009) Production of prodigiosin from Serratia 14 
 marcescens and its cytotoxicity activity. J Pharm Res 2:590-593 15 
Ramani D, Nair A, Krithika K (2014) Optimization of cultural conditions for the production of prodigiosin 16 
 by Serratia marcescens and screening of the antimicrobial activity of prodigiosin. Int J Pharma Bio 17 
 Sci  5:383-392 18 
Roy P, Ahmed NH, Grover RK (2014) Non-pigmented strain of Serratia marcescens: An unusual pathogen 19 
 causing pulmonary infection in a patient with malignancy. J Clin Diagn Res 8:DD05-DD06. doi: 20 
 10.7860/JCDR/2014/8629.4513 21 
Seah SW, Nathan S, Wan KL (2016) Toxicity evaluation of prodigiosin from Serratia marcescens in a 22 
 Caenorhabditis elegans model. AIP Conf Proc 1784. P. 020015. doi:10.1063/1.4966725 23 
Seganish JL, Davis JT (2005) Prodigiosin is a chloride carrier that can function as an anion exchanger. 24 
 Chem Commun (Camb) 46:5781-5783. doi: 10.1039/b511847f 25 
Shaikh Z (2016) Biosynthesis of prodigiosin and its applications. IOSR J Pharm Biol Sci 11:1-28. doi: 26 
 10.9790/3008-1106050128 27 
Siva R, Subha K, Bhakta Ghosh AR, Babu S (2011) Characterization and enhanced production of 28 
 prodigiosin from the spoiled coconut. Appl Biochem Biotechnol 166:187-196.  doi: 29 
 10.1007/s12010-011-9415-8 30 
Solovyev V, Salamov A (2011) Automatic annotation of microbial genomes and metagenomic 31 
 sequences. In: Li RW (ed) Metagenomics and its applications in agriculture, biomedicine and 32 
 environmental studies. Nova Science Publishers, New York, pp 61-78 33 
Song MJ, Bae J, Lee DS, Kim CH, Kim JS, Kim SW, Hong SI (2006) Purification and characterization of 34 
 prodigiosin produced by integrated bioreactor from Serratia sp. KH-95. J Biosci Bioeng 101:157–161. 35 
 doi:10.1263/jbb.101.157 36 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 21 
 
Soto-Cerrato V, Vinals F, Lambert JR, Perez-Tomas R (2007) The anticancer prodigiosin induces 1 
 p21WAF1/CIP1 expression via transforming growth factor-beta receptor pathway. Biochem 2 
 Pharmacol 74:1340-1349. doi: 10.1016/j.bcp.2007.07.016 3 
Spiteller P, Kern W, Reiner J, Spiteller G (2001) Aldehydic lipid peroxidation products derived from 4 
 linoleic acid. Biochim Biophys Acta 1531:188–208. doi: 10.1016/S1388-1981(01)00100-7 5 
Stankovic N, Senerovic L, Ilic-Tomic T, Vasiljevic B, Nikodinovic-Runic J (2014) Properties and 6 
 applications of undecylprodigiosin and other bacterial prodigiosins. Appl Microbiol Biotechnol 7 
 98:3841-3858. doi: 10.1007/s00253-014-5590-1 8 
Sumathi C, MohanaPriya D, Swarnalatha S, Dinesh MG, Sekaran G (2014) Production of prodigiosin using 9 
tannery fleshing and evaluating its pharmacological effects. ScientificWorldJournal. 10 
doi:10.1155/2014/290327 11 
Sun SQ, Wang YJ, Xu W, Zhu CJ, Liu XX (2015) Optimizing ultrasound-assisted extraction of prodigiosin 12 
by response surface methodology. Prep Biochem Biotechnol 45:101-108. doi: 13 
10.1080/10826068.2013.877029 14 
Suryawanshi RK, Patil CD, Koli SH, Hallsworth JE, Patil SV (2016) Antimicrobial activity of prodigiosin 15 
 is attributed to plasma-membrane damage. Nat Prod Res 31. doi:10.1080/14786419.2016.1195380 16 
Urtishak KA, Edwards AY, Wang LS, Hudome A, Robinson BW, Barrett JS, Cao K, Cory L, Moore JS, 17 
 Bantly AD, Yu QC, Chen IM, Atlas SR, Willman CL, Kundu M, Carroll AJ, Heerema NA, Devidas 18 
 M, Hilden JM, Dreyer ZE, Hunger SP, Reaman GH, Felix CA (2013) Potent obatoclax cytotoxicity 19 
 and activation of triple death mode killing across infant acute lymphoblastic leukemia. Blood 121: 20 
 2689–2703. doi: 10.1182/blood-2012-04-425033 21 
Venil CK, Velmurugam P, Lakshmanaperumalsamy P (2009) Genomic environment of cueR and copA 22 
 genes for prodigiosin biosynthesis by Serratia marcescens SB08. Rom Biotechnol Lett 14:4812-4819 23 
Wang B, Lin L, Lu L, Chen W (2012a) Optimization of β-carotene production by newly isolated Serratia 24 
 marcescens strain. Electron J Biotechnol 15. doi:10.2225/vol15-issue6-fulltext-4 25 
Wang F, Luo HL, Song GH, Liu C, Wang JG, Xu JL, Su XH, Ma XY (2013) Prodigiosin found in Serratia 26 
 marcescens y2 initiates phototoxicity in the cytomembrane. Electron J Biotechnol 16. 27 
 doi:10.2225/vol16-issue4-fulltext-7 28 
Wang SL, Wang CY, Yen YH, Liang TW, Chen SY, Chen CH (2012b) Enhanced production of insecticidal 29 
 prodigiosin from Serratia marcescens TKU011 in media containing squid pen. Process Biochem 30 
 47:1684-1690. doi: 10.1016/j.procbio.2011.07.010 31 
Wilft NM, Salmond GPC (2012) The stationary phase sigma factor, RpoS, regulates the production of a 32 
 carbapenem antibiotic, a bioactive prodigiosin and virulence in the enterobacterial pathogen Serratia 33 
 sp. ATCC 39006. Microbiology 158:648-658. doi: 10.1099/mic.0.055780-0 34 
Williamson NR, Fineran PC, Leeper FJ, Salmond GPC (2006a) The biosynthesis and regulation of bacterial 35 
 prodiginines. Nat Rev Microbiol 4:887-899. doi: 10.1038/nrmicro1531 36 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 22 
 
Williamson NR, Simonsen HT, Ahmed RAA, Goldet G, Slater H, Woodley L, Leeper FJ, Salmond GP 1 
(2005) Biosynthesis of the red antibiotic, prodigiosin, in Serratia: identification of a novel 2 
2-methyl-3-n-amyl-pyrrole (MAP) assembly pathway, definition of the terminal condensing enzyme, 3 
 and implications for undecylprodigiosin biosynthesis in Streptomyces. Mol Microbiol 56:971–4 
989. doi: 10.1111/j.1365-2958.2005.04602.x 5 
Williamson NR, Simonsen HT, Harris AKP, Leeper FJ, Salmond GPC (2006b) Disruption of the copper 6 
 efflux pump (CopA) of Serratia marcescens ATCC 274 pleiotropically affects copper sensitivity and 7 
 production of the tripyrrole secondary metabolite, prodigiosin. J Ind Microbiol Biotechnol 33:151-158. 8 
 doi: 10.1007/s10295-005-0040-9 9 
Xu F, Xia SX, Yang QY (2011) Strategy for obtaining inexpensive prodigiosin production by Serratia 10 
 marcescens. 3rd Int Proc Chem Biol Environ Eng 20:32-36 11 
Yip CH, Yarkoni O, Ajioka J, Wan KL, Nathan S (2018) Development of a codon optimization strategy 12 
using the eforRED reporter gene as a test case. AIP Conf Proc 1940. P. 020080. doi: 13 
10.1063/1.5027995. 14 
Yip CH, Yarkoni O, Mario J, Ajioka J, Wan KL, Nathan S (in press) The Escherichia coli motA flagellar 15 
gene as a potential integration site for large synthetic DNA. Sains Malays 16 
You ZY, Zhang SP, Liu XX, Wang YJ (2018) Enhancement of prodigiosin synthetase (PigC) production 17 
from recombinant Escherichia coli through optimization of induction strategy and media. Prep 18 
Biochem Biotechnol 48:226-233. doi: 10.1080/10826068.2017.1421965 19 
Zhang B, Zhang L, Dai RX, Yu MY, Zhao GP, Ding XM (2013) An efficient procedure for marker-free 20 
 mutagenesis of S. coelicolor by site-specific recombination for secondary metabolite overproduction. 21 
 PLoS One 8. doi:10.1371/journal.pone.0055906 22 
Zhou W, Li JH, Chen J, Liu XY, Xiang TT, Zhang L, Wan YJ (2016) The red pigment prodigiosin is not an 23 
 essential virulence factor in entomopathogenic Serratia marcescens. J Invertebr Pathol 136:92-94. doi: 24 
 10.1016/j.jip.2016.03.011 25 
 26 
 27 
 28 
 29 
 30 
 31 
 32 
 33 
 34 
 35 
 36 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 23 
 
Table 1 Function of each Pig protein involved in the biosynthesis of prodigiosin (Adapted from 1 
Williamson et al. 2005) 2 
 3 
Protein Pathway Function 
PigA MBC L-prolyl-PCP dehydrogenase 
PigB MAP H2MAP dehydrogenase 
PigC Condensing Condensing enzyme 
PigD MAP 2-Acetyloctanal synthase 
PigE MAP 2-Acetyloctanal aminotransferase 
PigF MBC HBC O-methyl transferase 
PigG MBC Peptidyl carrier protein 
PigH MBC HBM synthase 
PigI MBC L-prolyl-AMP ligase 
PigJ MBC Pyrrolyl-β-ketoacyl ACP synthase 
PigK MBC Specific function unknown but may act as molecular chaperone to other 
Pig enzymes in protein folding 
PigL MBC 4’-Phosphopantetheinyl transferase 
PigM MBC HBM dehydrogenase 
PigN MBC Specific function unknown but is believed to methylate HBC to MBC 
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